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Sortases are cysteine transpeptidases found primarily on the cell surface of Gram-positive 
bacteria. Sortase-mediated ligations have become an attractive option for protein modification 
chemistry, enabling the synthesis of a wide range of non-natural polypeptide derivatives.  Attempts 
at understanding how these enzymes recognize and bind substrates are integral to furthering their 
usefulness in protein engineering and, potentially, treatment of bacterial diseases. However, the 
variable substrate specificity and activity between homologs of these enzymes is not yet fully 
understood. Of specific interest to us is sortase A from Streptococcus pneumoniae (SrtApneu), as it 
demonstrates a broad substrate tolerance not observed in other sortase A homologs. 
Correspondingly, we have made advances towards characterizing a substrate bound structure of 
SrtApneu in an effort to further understand its unique substrate promiscuity, deviating from the 
canonical LPXTG sorting signal. Our strategy initially involved generating a non-cleavable 
peptide analog capable of docking into the active site, however, synthesis of a ketomethylene-
linked dipeptide isostere and its insertion into a peptide via solid phase peptide synthesis proved 
to be more challenging than we anticipated. We revised our approach by designing a substrate 
harboring an LPACG sorting motif. Peptide preparations with a thiopyridine leaving group 
favorably facilitated disulfide bridging between the active site and sorting motif cysteines, 
allowing for elucidation of a SrtApneu structure displaying key interactions that allow the enzyme 
to recognize a wide-variety of substrates. To this end, we have utilized x-ray crystallography and 
solution NMR in an attempt to characterize SrtApneu with a bound substrate analog. Although we 
were unsuccessful, this work has established a foundation for future efforts toward determining 
the substrate-bound structure of SrtApneu.  
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Chapter 1 – Introduction 
1.1 Protein Engineering - Advantages of Chemoenzymatic Modification 
Contemporary pursuits toward endowing proteins with unnatural or non-canonical 
functionalities, known as protein engineering, has garnered significant attention across academic, 
industrial and medical applications.1–4 Protein engineering efforts were historically limited to 
molecular biology techniques to install protein modifications genetically, which were applied 
through single-point mutations as well as frameshift sequence insertions and deletions.5 The 
modern utility of mutagenic techniques, such as directed evolution and unnatural amino acid 
incorporation, have dramatically broadened the variety of protein modifications, however, these 
methods continue to be burdened by substantial time and cost investments.6–10 In contrast, protein 
modification through novel direct chemical ligation strategies is a relatively quick and cost-
effective way of engineering proteins. This bioconjugation technique takes advantage of the 
natural reactivity of sterically unencumbered amino acid side chains (i.e. lysine, cysteine, glutamic 
and aspartic acids), which is optimal for generating proteins with non-natural modifications.11–15 
While these contemporary modification strategies have revolutionized protein engineering, 
continuing to expand the scope and efficacy of direct protein bioconjugation is critical for the 
advancement of several fields, including fundamental biochemistry, the design of protein 
therapeutics, and the generation of new biomaterials.  
 
Chemoenzymatic modification of proteins has provided an attractive alternative to site-
directed mutagenesis and direct chemical modification strategies. This bioconjugation technique 
has been utilized in a variety of instances, including the production of fluorescently labeled 
proteins for live-cell trafficking, antibody-drug conjugates for site-specific payload delivery, and 
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adhering protein to nanoparticles.16–18 In chemoenzymatic modification, a sequence of amino acids 
is recognized by the modification enzyme, which results in the site-specific attachment of the 
desired moiety (Figure 1). If an endogenous protein target does not possess the required 
recognition sequence, which is often the case, then a recognition site must be added, typically 
using site-directed mutagenesis.19 There is a continuously expanding assortment of modifications 
that can be installed using chemoenzymatic modification strategies, along with a growing catalog 
of enzymes able to catalyze these processes. 
A notable example of an enzyme used in chemoenzymatic strategies is formylglycine 
generating enzyme (FGE), which recognizes a CXPXR sequence of amino acids, then modifies 
the cysteine residue to a formylglycine reaction handle commonly utilized for generating stable 
oxime ligation products.20–22 Lipoic acid ligase has seen use through similar bioorthogonal ligation 
approaches, wherein this enzyme canonically functions to adhere lipoic acid to the ε-amine of 
lysine side chains within the primary sequence of its target protein.23 Interestingly, this 
promiscuous enzyme has demonstrated the ability to install a diverse variety of substrates, notably 
azide and alkyne containing click handles, which has significantly broadened the scope of site-
Modification 
Modification Enzyme 
Protein Target Modified Protein 
Figure 3. Generic Schematic of Chemoenzymatic Protein Labeling. A protein (left) harboring a binding 
motif is recognized by the modification enzyme, then the modification is covalently attached to the protein 
target (right). 
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specific modifications that can be installed using lipoic acid ligase.24 Biotin ligase manifests a 
similar behavior, where it covalently attaches a biotin residue to the ε-amine of the lysine side 
chain within its target recognition sequence.25 Biotin-based protein engineering has attracted 
attention due to its robust function as a site-specific tag for binding streptavidin or avidin 
containing biomolecules, including functionalized nano-particles or quantum dots, with 
exceptional specificity and pico-molar affinity.26,27 
 
The sortase enzyme family has also been extensively studied for its utility in protein 
modification. Sortases are endogenous to Gram-positive bacteria, where they function as 
transpeptidases through a catalytic mechanism involving a nucleophilic cysteine within the 
enzyme’s active site.28–30 Sortases are separated into distinct classes (A-F) based on their unique 
contrasting structural and biochemical traits.31,32 Class A sortases (SrtA) have demonstrated the 
most relevance to protein engineering, having been recombinantly expressed with a truncated N-
terminus to remove the transmembrane domain, which has resulted in a soluble derivative of SrtA 
for in vitro ligation reactions. In vivo, SrtA performs an essential “housekeeping” role in 
maintaining the extracellular environment by anchoring a variety of proteins to the cell wall.33–36 
Proteins appended to the extracellular matrix by SrtA are key virulence factors, including collagen 
adhesion proteins as well as fibronectin and immunoglobulin binding proteins, that are responsible 
for bacterial cell colonization and evading host immune detection.37–42 The in vivo function of SrtA 
has been highlighted as a viable drug target in Gram-positive bacteria, as studies have reported a 
dramatically reduced virulence of SrtA knockout Gram-positive bacterial strains.43–47 As the 
catalog of ineffective antibiotic drugs continues to rapidly expand, it has become imperative to 
develop an in-depth understanding of sortase structure and enzymology to further the development 
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of novel therapeutics while simultaneously providing insight into their role in protein 
engineering.48 
Sortase A enzymes share a common mechanism of action involving the recognition of a 
five amino acid sequence, which will hereafter be referred to as a “sorting motif”. The most 
common sorting motif for SrtA enzymes is the LPXTG sequence, where X is any amino acid.31,32 
However, it is now known that different SrtA homologs can recognize a number of variations of 
the standard LPXTG sequence. Sortase A from Staphylococcus aureus (SrtAstaph) recognizes a 
protein substrate harboring an LPXTG sorting motif (Figure 2).36 Next, the active site cysteine 
cleaves the amide bond between threonine and glycine, which releases the excised C-terminal 
fragment from the substrate. A transient acyl enzyme intermediate is formed through this process, 
and the scissile thioester linkage is subsequently intercepted by nucleophilic attack of the N-
terminal amine of a pentaglycine peptide of lipid II anchored to the peptidoglycan matrix. 
Reconstitution of the amide bond linkage fuses the protein to the peptidoglycan, at which point the 
protein substrate is released from the active site and the enzymatic potency of SrtAstaph is restored 
for additional catalytic cycles. 
Figure 4. Overview of SrtA in vivo mechanism on surface of Staphylococcus aureus. 
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In vitro, SrtA enzymes have been utilized extensively in protein engineering chemistry due to their 
ability to catalyze site-specific modifications at the sorting motif. Recent efforts that have used 
this approach include conjugating proteins and peptides to fluorophores, nanoparticle solid-
supports, synthetic peptides, surfaces of live cells and other proteins (Figure 3).49–53    
This by no means encapsulates the full breadth of modifications that can be achieved using 
sortase-mediated ligation (SML), and we refer the reader to other excellent reviews for more 
comprehensive discussions of SML applications.54–58 One of the key factors in the versatility of 
SML is the ability of users to control which reaction partner is functioning as the LPXTG-substrate 
and which is serving as the reaction nucleophile.59–61 In doing so, one is able to use SML for 
appending modifications to exposed C- and N-termini, and in some cases sterically unencumbered 
secondary structures. To date, the majority of these SML studies have utilized wild-type SrtAstaph. 
However, over the past decade a number of efforts to improve the properties of SrtAstaph have 
Figure 3. Protein modification using model SML. 
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resulted in evolved mutants demonstrating improved reaction rates, non-canonical substrate 
tolerances, and Ca2+ cofactor independence.62–65 These evolved variants now provide a range of 
sortase derivatives that can be selected for specific applications.  
 
1.2 Expanded Substrate Tolerance of Sortase Homologs 
As noted above, there exists a diverse archive of published protein engineering applications 
utilizing sortase-mediated ligation, which is continually expanding along with contemporary 
efforts to circumvent limitations historically associated with this technique. Notably, issues 
associated with SML include the slow reactions rates of ligations using SrtAstaph, reaction 
reversibility, strict substrate specificity, and a narrow scope of compatible amine nucleophiles.66–
68 Of relevance to this thesis, there have now been reported multiple studies on expanding the 
substrate scope of SML using either SrtAstaph mutants or other naturally occurring sortase 
homologs.63,64,69–71 
 
Bioinformatic investigations of SrtA homolog specificities through the CW-PRED2 
genome alignment algorithm has revealed a universal preference for LPXTG motifs.65,72 In vitro 
analysis of SrtA preferences with computationally derived peptide substrates have revealed 
        Table 2. Substrate specificity of Sortase A mutants and wild-type homologs. 
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discrepancies between actual and predicted SML compatible sorting sequences (Table 1). Notably, 
Kruger et al. have experimentally demonstrated that SrtAstaph tolerates LPXXG substrates, and 
exhibits a preference for glycine in the 6th position, outside of the canonical LPXTG sorting 
motif.73 Phage and yeast display directed evolution studies have generated evolved variants of 
SrtAstaph with alternative substrate preferences.
64,69 These SrtAstaph mutants have exhibited a 
relaxed substrate tolerance for residues in 1st, 2nd and 4th position.  
 
Randomization of the β6/β7 loop among SrtAstaph mutants revealed evolved variants 
selective for FPXTG or APXTG motifs.64 Rather than genetically modifying the substrate 
preferences of SrtAstaph, others have taken the approach of exploiting the natural reactivity and 
specificity of different SrtA homologs.70,71 The model enzyme for SML has historically been wild-
type SrtAstaph, however, a notable endogenous SrtA homolog from streptococcus pyogenes 
(SrtApyogenes) has revealed advantages beyond the utility of SrtAstaph. SrtApyogenes is capable of 
recognizing a diverse catalog of substrates, which has enabled a multifaceted approach to site-
specifically modify different regions within a single protein target.19 Furthermore, SrtApyogenes is 
capable of generating isopeptide bonds by accepting ε-amine of lysine, as well as processing the 
N-terminal amines of glycine, serine, and even D-asparagine residues.74 In general, streptococcal 
sortases have exhibited promiscuous substrate preferences, and an unprecedented tolerance for 
LPXLG motifs, which may be useful for SML reactions.71 To date, sortase A homologs employed 
for SML reactions represent only a fraction of the thousands of sortase genes encoded by genomes 
across the bacterial kingdom.75,76 Therefore, there exists an untapped potential for harnessing the 
reactivity of sortase A homologs to broaden the scope of applicable SML substrates. Our lab has 
highlighted this concept by determining the substrate preferences of eight naturally occurring SrtA 
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homologs, each exhibiting a preference for residues across each position along the sorting motif.70 
Positions 4 and 5 displayed significant deviation from the canonical LPXTG sorting motif, where 
many SrtA homologs preferred substrates with several different amino acids in the 5th position. 
Notably, sortase A from Streptococcus pneumoniae (SrtApneu) demonstrated the broadest substrate 
tolerance of non-canonical amino acids in the 5th position (Figure 4). 
Although SrtApneu recognizes a variety of sorting motifs, high performance liquid 
chromatography (HPLC) and mass spectrometry (MS) analyses of product conversion from model 
SML reactions revealed a strong preference for an LPATA substrate in vitro, which is strikingly 
different than the LPETG preference for SrtAstaph. The SrtA reactivity and specificity trials we’ve 
published may persuade the reader to believe that SrtA is not appropriate for SML applications 
based on the suboptimal product conversion of various substrates. However, the data presented is 
reflective of unoptimized reactions, where even the lowest substrate conversion can be drastically 
Figure 4. Comparison of substrate preferences for the 5th position of the sorting motif among SrtA 
homologs.70 These values represent % conversion of substrate to excised fragment. No cleavage was 
observed for X = P, T, I, D, E, R, K, H. 
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improved by redesigning the reaction conditions. The utility of SrtApneu has provided an 
opportunity to bolster the applicability of SML protein engineering by broadening the scope of 
substrate targets. As a result, SrtApneu has potentially reduced the necessity to mutagenically 
implement a sorting motif into protein targets, which improves the compatibility of SML for 
endogenous proteins. The unique substrate promiscuity of SrtApneu has potentiated an interest 
toward elucidating active site residues responsible for dictating the mechanism of recognition. A 
deep understanding of these interactions on a molecular level would likely provide insight to this 
phenomenon, which will advance our understanding of sortase enzymology and sortase-mediated 
chemistry. The structure of SrtApneu has not been published, which has compelled our efforts 
toward an in-depth analysis of SrtApneu substrate recognition through structural characterization.  
 
1.3 Substrate Binding and Structural Characteristics of SrtA Homologs 
Multiple structures of various SrtA homologs have been published over the last decade, 
which were either characterized by X-ray crystallography or solution nuclear magnetic resonance 
(NMR) spectroscopy. Published structures of SrtAstaph have aided in developing an improved 
understanding of enzyme-substrate binding interactions with residues in the sorting motif, and 
insight into the reverse protonation mechanism instigating transpeptidation reactions.77,78 
Published structures of SrtA homologs manifest an 8-stranded β-barrel fold, which is a conserved 
feature across SrtA enzymes.30 Strands comprising the β-barrel are flanked by a series of alpha 
and 310 helices, as well as disordered loops varying in size and position among homologs.
31,33,79–82 
In general, SrtA enzymes share an evolutionarily conserved active site housing three catalytic 
residues; a cysteine to establish a transient thio-acyl linkage, a histidine to facilitate thiolate 
formation, and an arginine thought to provide hydrogen bonding to stabilize active site residues 
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essential for catalysis.33,83 In the case of SrtAstaph, the floor of the active site, or binding groove, is 
formed by β4 and β7 loops and the adjacent walls are composed conjoining loops, and helices. The 
binding pocket adopts the appearance of a bent “L” shape, which may justify the necessity for 
proline in the 2nd position of the sorting motif as it situates the amide bond linking 4th and 5th 
position residues towards the active site cysteine.78 The non-polar carbon fork of the 1st position 
leucine establishes hydrophobic contacts with residues in the β6/β7 loops, and the 2nd position 
proline is buried within a hydrophobic cleft formed by residues in β4 and β7 strands. The 3rd 
position alanine maintains distant hydrophobic interactions with the H1 helix, which may provide 
a rationale for the indiscriminate preference for residues in this position as there exists ample space 
for cumbersome side chains. The 4th position threonine pushes a nearby tryptophan residue 
(Trp194) out of the active site, which situates the active site cysteine in proximity to the scissile 
peptide bond. Preservation of threonine is critical for this mechanism, as substrates substituting 
glycine in the 4th position are unreactive. The 5th position glycine is predicted to associate with the 
β7/β8 loop, which hypothetically undergoes a distinct transition to a structurally ordered 
conformation upon substrate docking.78,84–86 Preferential recognition of the 5th position residue is 
anticipated to be partially dependent on the length of the β7/β8 loop. SrtAstaph has a relatively large 
β7/β8 loop compared to other homologs, which may condone the stringent selectivity for glycine 
in the 5th position of the sorting motif. After substrate docking is facilitated, nucleophilic attack 
of the scissile peptide bond by the active site cysteine repositions the β7/β8 loop further from the 
binding pocket, revealing a sterically unencumbered site for incoming nucleophiles.78 
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The substrate bound SrtAstaph complex published by Suree et al. has constructed a 
framework for interpreting the role of each residue positioned along the LPAT substrate analog 
and deciphering crucial interactions with residues housed within the active site (Figure 5).78   
Figure 5. (A) Solution NMR structure of SrtAstaph. Arginine (cyan), cysteine (magenta), and histidine 
(blue) stick structures represent catalytic residues in the enzyme active site. (B) Predicted structure of 
SrtApneu based on a one-to-one threading model of SrtApyogenes (PDB ID: 3NF7) from the Phyre2 
structural prediction server. (C) Solution NMR structure of the SrtAstaph active site with a bound LPAT* 
substrate analog (PDB ID: 2KID). Side chains of residues comprised within the active site are shown 
as stick structures, highlighting several hydrophobic interactions stabilizing the substrate-bound state. 
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Unfortunately, this systematic model fails to provide a holistic depiction of SrtA substrate 
recognition and binding since the substrate analog only contains the first four amino acids (LPAT) 
in the sorting sequence. As a result, identifying active site residues that interact with the 5th position 
residue of a target sorting motif is challenging based on this model. However, Suree and coworkers 
illuminated regions in SrtAstaph thought to be responsible for recognizing the 5
th position residue 
in the sorting motif as well as coordinating entry of the incoming nucleophile. 
Three regions in SrtAstaph displayed significant alterations in their backbone resonances in 
the presence of a triglycine nucleophile, which was monitored using 15N heteronuclear single 
quantum coherence (HSQC) NMR (Figure 6).87 Residues harbored within these regions are likely 
Figure 6. Sequence alignment of selected SrtA homologs. The regions of greatest difference (boxed) 
correspond to the regions highlighted in the structure (right), indicating the least sequence homology 
on the structural features predicted to interact with the 5th position of the sorting sequence. The structure 
(right) is a surface representation of SrtAstaph bound to a substrate analog LPAT* (PDB ID: 2KID). 
Residues highlighted in magenta were determined to interact with the incoming nucleophile by analysis 
of peak perturbation during an 15N-HSQC monitored titration of SrtAstaph with triglycine. These residues 
are primarily situated around the region of the binding pocket and are predicted to interact with the C-
terminus of the sorting signal.   
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contacting the 5th position residue of the sorting motif, which suggests that they are critical for 
substrate recognition. Sequence alignments of SrtA homologs indicated distinct differences in 
primary structure within these regions, which provides a rationale for the diverse tolerance of 
various residues in the 5th position. This evidence coincides with our experimental findings, where 
SrtA homologs demonstrated a variety of preferences for the 5th position residue. Supplementary 
assessments are necessary to establish a more thorough understanding of SrtA substrate 
recognition. 
A 3D domain swapped structure of SrtApneu has been deposited in the Protein Data Bank 
(PDB ID: 4O8L), but monomeric enzyme with (or without) bound substrate has not yet been 
characterized (Figure 7). A structure of monomeric SrtApneu bound to a substrate may distinguish 
Figure 7. (A) The 3D domain swapped dimer of SrtApneu (PDB ID: 4O8L). (B) A domain swapped 
monomer from the dimeric structure of SrtApneu. (C) Predicted structure of SrtApneu based on a one-to-
one threading model of SrtApyogenes (PDB ID: 3FN7) from the Phyre288 structural prediction server. In 
both (B) and (C) structures, the red colored regions resemble the domain swapped portion of the 
structure shown in (A). 
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novel features that are responsible for its unique substrate tolerance, similar to aforementioned 
efforts toward determining which active site residues contribute to substrate recognition in 
SrtAstaph. Phyre2 structural prediction algorithms have served as a preliminary means of 
determining which residues perpetuate the promiscuous substrate tolerance of SrtApneu.
88 Structure 
predictions suggest that SrtApneu to has a smaller β7/β8 loop than SrtAstaph, which may confer a 
broader substrate tolerance, as this loop region is thought to be important for recognizing the 5th 
position residue of the sorting motif.  
 
1.4 SrtApneu Enzyme Activity as a Function of Oligomeric State 
The structure of monomeric SrtApneu has yet to be determined, however, the dimeric form 
of the enzyme has piqued our interests toward understanding the mechanism of assembly in vivo 
and in vitro, as well as its role on enzyme activity. In previous SrtApneu studies, we sought to 
evaluate the catalytic activity of both dimeric and monomeric forms of the enzyme.70 These 
multimers were identified in an IMAC elution of purified SrtApneu by native-PAGE, where 
numerous distinct bands were observed, as opposed to SDS-PAGE analysis displaying a single 
band. In model SML studies, we hypothesized that monomeric SrtApneu was an active form of the 
enzyme, whereas multimeric forms were thought to be an inactive form, based on their activity in 
the presence of an Abz-LPATAG-K(Dnp) peptide substrate and a potent hydroxylamine (NH2OH) 
nucleophile (Figure 8). Model SML reactions utilizing multimeric SrtApneu rapidly plateaued with 
minimal product formation (21% product conversion). Conversely, identical reactions involving 
monomeric SrtApneu achieved significantly higher product formation (95% product conversion). 
To confirm our suspicions, size exclusion fast protein liquid chromatography (SE-FPLC) was 
utilized to confirm the presence of all SrtApneu assemblies. The spectra revealed multiple species 
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varying in molecular weight, and native-PAGE bands of respective fractions travelled identical to 
native-PAGE bands of a SrtApneu heterogeneous mixture. 
Bacterial expression of a truncated SrtApneu clone (Δ80) generated substantial amounts of 
inactive enzyme, thus it became imperative to explore options allowing us to regenerate fully 
active monomeric SrtApneu.
70 We initially proposed the idea of subjecting SrtApneu to conditions 
eliciting the disassembly of all SrtApneu multimers, followed by the refolding of denatured SrtApneu 
to monomeric enzyme. Our original hypothesis speculated that SrtApneu dimerization is an 
equilibrium driven process, where acute concentrations of enzyme may shift the equilibrium 
toward an energetically favorable dimeric fold. Attempts to incubate serial diluted samples at room 
temperature sought to evaluate this possibility. Contrary to our rationale, the intensity of a dimeric 
Figure 8. RP-HPLC analysis of model SML reactions demonstrating the difference in activity 
between monomeric (top) and multimeric (bottom) SrtApneu preparations.70 
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SrtApneu band in a native-PAGE gel remained unaffected. We proposed the possibility that SrtApneu 
dimerization is co-translational phenomenon, where artificially elevated concentrations in-vivo 
may instigate a dimeric fold. If true, we anticipated that dismantling SrtApneu assemblies during 
purification, followed by refolding under native conditions, may provide an opportunity for 
SrtApneu to reassemble into monomeric enzyme. A denaturing agent capable of disrupting any 
intermolecular interactions, namely domain swapping contacts, was implemented in our IMAC 
purification buffers. Specifically, we employed an initial denaturing IMAC purification using 8 M 
urea, where E. coli cells were lysed under denaturing conditions, the protein was purified from 
clarified lysate in denaturing buffer via IMAC, followed by a rapid dilution of denaturing eluate 
in non-denaturing buffer to refold monomeric enzyme. The non-denatured diluted protein was 
reconcentrated by a non-denaturing IMAC purification, and eluted fractions were further purified 
by SE-FPLC to isolate residual dimers from reassembled monomeric enzyme. We also added 
tris(carboxyethyl)phosphine (TCEP), a non-sulfurous reducing agent, to our IMAC purification 
buffers to disfavor cysteine disulfide bridging between monomers and preserve the reduced form 
of the thiol. Overall, our enzyme refolding protocol in tandem with SE-FPLC enrichment 
significantly improved SrtApneu monomer recovery (Figure 9). Furthermore, the regenerated 
SrtApneu monomer performed identical to previous model SML reactions, where 95% conversion 
was observed for the refolded enzyme.  
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Supplementary investigations have revealed the presence of both monomeric and dimeric 
forms of SrtAstaph in vivo and in vitro.
89–91 The in vitro catalytic activity of monomeric SrtAstaph 
has been evaluated by Lu and coworkers, where ligation reactions with homodimeric preparations 
demonstrated superior product conversion compared to monomeric enzyme. In contrast, the 
insertion of a non-dimerizing SrtAstaph mutant in a knockout strain of S. aureus by Zhu et al. 
resulted in an increased presence of sortase-catalyzed surface anchored proteins in vivo, which 
provides evidence in support of a catalytically active SrtAstaph monomer. In vivo observations of 
SrAstaph activity as a function of oligomerized state are in clear contrast to in vitro studies, but 
coincide our evidence indicating monomeric SrtApneu is the catalytically active form in vitro. The 
pervasive dimerization among SrtA homologs has raised questions regarding the biological 
significance of these dimers, as they are anticipated to serve as a means of regulating enzyme 
deactivation when extracellular protein appendage is unnecessary.89,91 This proposed mechanism 
of regulation is not unfounded, as there exists many enzymes (i.e. phospholipase) that are governed 
in this fashion.92 Although interplay between monomeric and dimeric forms of SrtAstaph and 
Figure 9. A comparison of standard vs. refolded SrtApneu preparations via SE-FPLC (left). Native-
PAGE analysis of isolated monomeric (M) fractions and dimeric (D) fractions by SE-FPLC (right). 
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SrtApneu has been evaluated, similar investigations have not been geared toward other SrtA 
homologs. 
 
1.5 Overview of Project Goals 
The modern utility of sortases as a tool for protein engineering has broadened the 
accessibility of site-directed ligation chemistry, which is substantiated by previous efforts toward 
understanding substrate tolerance among sortase homologs and the circumvention of limitations 
historically plaguing sortase-mediated ligation techniques. The continued development of this 
system is hinges upon our ability to develop a structure-function relationship among sortases in an 
effort to improve our knowledge of substrate recognition among homologs with diverse substrate 
tolerances. To this end, the long-term goal of this project is to determine the structure of SrtApneu 
covalently docked with a peptide inhibitor as a means to identify novel interactions with active-
site residues prompting a unique promiscuous substrate tolerance. As described in this thesis, 
preliminary investigations of monomeric SrtApneu structure involved protein crystallography 
followed by X-ray diffraction. Concurrently, we have attempted to construct a non-cleavable 
ketomethylene-based sorting motif analogs in an effort to prolong occupancy within the SrtApneu 
active site. Sorting motif substitution of 4th and 5th position residues with ketomethylene dipeptide 
was anticipated to mimic the performance of canonical SrtApneu substrates. Unfortunately, the 
challenging synthesis of a solid-phase ready ketomethylene dipeptide and the rapid degradation of 
ketomethylene-based substrates depreciated effectiveness of this approach. Correspondingly, 
we’ve redesigned our canonical SrtApneu substrate sorting motif with a cysteine residue in the 4th 
position. We believe this substrate analog will establish a disulfide linkage with the active site 
cysteine, allowing for elucidation of key interactions between the enzyme and residues positioned 
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along the sorting motif. Identification of substrate bound SrtA complex via LC-ESI-MS has 
propelled our efforts toward determining the structure using HSQC NMR.  
 
Chapter 2 – Screening Studies for X-ray Crystallography of SrtApneu 
2.1 Preparation of SrtApneu for Crystallization  
Prior to screening crystallization conditions, it was first necessary to generate suitable 
preparations of the SrtApneu enzyme that were monomeric. To this end, an expression vector 
encoding a truncated version of SrtApneu lacking the first 80 residues (hereafter referred to as 
simply SrtApneu) and fused to an N-terminal His6 tag was obtained. In this construct, the 
hydrophobic transmembrane domain was removed to increase the in vitro solubility of SrtApneu in 
aqueous buffers. A glycerol stock of transformed E. coli BL21 (DE3) was used to express SrtApneu 
using standard molecular biology techniques. After denaturing cell lysis using 8 M urea, the 
enzyme was separated from the cellular debris via centrifugation, then isolated from the 
supernatant using immobilized metal affinity chromatography (IMAC) under denaturing 
conditions (Figure 10, lanes 2-6). The denatured protein eluate from IMAC was then diluted ten-
fold into a non-denaturing buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP) to refold 
SrtApneu, then repurified via IMAC under non-denaturing conditions to isolate soluble SrtApneu 
(Figure 10, lanes 7-10). The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) analysis of the refolded SrtApneu eluate revealed an intense band near 26 kDa, which was 
consistent with the calculated 20.1 kDa molecular weight of SrtApneu. This SDS-PAGE gel also 
showed the presence of a ~50 kDa SrtApneu dimer that persisted in the sample despite reducing and 
denaturing preparations.  
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In order to separate monomeric SrtApneu from higher order aggregates, the refolded protein 
solution was subjected to size exclusion chromatography (SEC). Monomeric fractions were 
collected and pooled, and analysis by analytical SEC revealed that final the protein preparation 
consisted of >85% monomer (Figure 11). Electrospray ionization mass spectrometry (ESI-MS) of 
the final monomer preparation reported a mass of 20,144 Da, in excellent agreement with the 
calculated molecular weight of 20,145 Da for SrtApneu (Figure 11). Taken together, SEC and ESI-
MS analyses provided evidence for a predominantly monomeric batch of SrtApneu, which was 





Figure 10. SDS-PAGE analysis of a SrtApneu IMAC/refolding purification scheme: (1) Protein 
molecular weight ladder, (2) cell lysate supernatant, (3) flow-through fraction of IMAC column under 
denaturing conditions, (4) denaturing wash, (5) 1st denaturing elution fraction, (6) 2nd denaturing elution 
fraction, (7) flow-through fraction of IMAC column following dilution of SrtApneu in non-denaturing 











Figure 11. SEC traces of IMAC purified, refolded SrtApneu (A) and collected monomeric fractions (B). 
A deconvolved mass spectrum (C) of SrtApneu generated from the (D) raw ESI-MS spectrum of the 
purified enzyme.  
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2.2 Summary of Crystal Screening Efforts 
With a monomeric batch of SrtApneu in hand, we turned our attention to screening 
conditions for crystallization of this enzyme. Initially, this involved utilizing vapor-drop diffusion 
methods for generating crystals. The concentrated stock of 6 mg/mL monomeric SrtApneu was 
screened against PEG/Ion2 and Index screening condition kits, each containing 48 and 96 different 
conditions, respectively. Four room temperature conditions from the Index screening kit produced 
a variety of crystal morphologies including wafer, rod, and asymmetric crystals (Table 2, Figure 
12).  
 
These crystallization conditions shared numerous similarities, which suggested that Bis-
Tris, pH 5.5, and polyethylene glycol (PEG) 3350 were promising components for inducing 
SrtApneu crystallization at room temperature. Based on this analysis, we sought to optimize these 
conditions by determining SrtApneu nucleation dependence as a function of pH and PEG 3350 
concentration (Figure 13).  
Figure 12. Crystals formed by 
screening conditions in Table 2. 
 
Table 2. Preliminary screening conditions resulting in 
crystal formation (pH 5.5, 25% PEG 3350, RT). 
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After two weeks, we observed the presence of crystals in conditions with low pH (4.5-5.5) 
and relatively high PEG 3350 concentration (24-26%). Microscopic investigation of crystals 
formed in the presence of these conditions revealed relatively small crystals that did not appear to 
have the defined 3D structure (i.e. hexagonal prism) of diffractable protein crystals.          
                                                                                     
Crystal screening was continued by maintaining 25% PEG 3350 and pH 4.5 or 5.5, 
however this time adjusting the concentrations of Bis-Tris (0.05-0.30 M) and other tuning salts 
(0.05-0.40 M). Hits were detected that produced crystals after two weeks, which essentially 
replicated the appearance of crystals grown in the previous pH/PEG optimization trial. Unlike the 
pH/PEG optimization trial, there was not a noticeable pattern indicating which salt/buffer 
concentrations favored crystal formation. This suggested that crystal growth and morphology was 
neither dependent on Bis-Tris nor tuning salt concentrations. It should be noted that each 
optimization trial was designed to replicate the initial screening conditions (#1-4) as a control, 








 % PEG  
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Figure 13. Crystal optimization as a function of pH and PEG 3350. The arrow represents the observed 
pattern of crystal formation, appearing more frequently as pH decreases and PEG 3350 increases.  
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the crystals we had generated were far from ideal for 
structure determination, we attempted to diffract our top 
candidates to determine whether we were generating salt 
or protein crystals (Table 3). Every crystal subjected to 
X-ray diffraction analysis displayed a prominent “ice 
ring” pattern, which occurs when the protein crystal is 
thawed and refrozen during transfer to the goniometer 
head of the diffractometer. Beyond this artifact, we 
didn’t observe any indication of a diffraction pattern corresponding to a proteinaceous crystal.  
 
We next tried crystallization conditions that were not included in either the PEG/Ion2 or 
Index crystal screening kits. Our previous screening efforts suggested that chloride-containing 
salts may promote crystal formation. Therefore, additional trials with potassium chloride (KCl), 
ammonium chloride (NH4Cl), or calcium chloride (CaCl2) tuning salts (0.05-0.40 M) in addition 
to Bis-Tris (0.05-0.30 M) were prepared. However, these did not demonstrate any capacity to grow 
diffractable crystals. We also attempted to modulate the standard 1:1 (2 µL drop) ratio of enzyme 
loading to mother liquor. Since we had observed some protein aggregation during pH/PEG 
optimization trials, we anticipated that a lower enzyme loading relative to mother liquor would 
slow nucleation and allow for improved crystal packing. Unfortunately, no crystals were observed 
using diluted SrtApneu preparations even months after plating. 
 
Finally, several months after our initial pH/PEG optimization trials, we did observe the 
presence of well-defined opalescent crystals in a well containing a replicate of the #4 screening 
Table 3. Diffracted crystals formed by 
conditions A-E (pH 5.5, 25% PEG 3350, 
RT). 
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condition (0.1 M BT, pH 5.5, 0.2 M MgCl2, 25% PEG 3350, RT). We attempted to loop these 
crystals, however, they had formed contacts with neighboring crystals and we were unable to 
effectively loop a single crystal without fracturing their structural integrity. In consideration of this 
promising result, we focused on optimizing condition #4 to recreate, and possibly improve, the 
iridescent crystals observed previously. Through the advice of our collaborators, we decided to 
optimize condition #4 by modulating PEG 3350 concentration as well as enzyme to mother liquor 
loading ratio. Several weeks after, we observed protein aggregation across over half of the 
preparations, and no sign of crystal formation.  
 
In summary, while we have been able to generate a monomeric preparation of SrtApneu, we 
have yet to identify conditions that produce crystals suitable for structure determination. Given the 
fact that multiple sortases have been successfully characterized using X-ray crystallography, we 
anticipate that monomeric SrtApneu will ultimately be amenable to X-ray characterization, however 
additional crystallization condition screening is required. In addition, it may be necessary to 
redesign the protein construct itself, as the 80 residue truncation or the presence of the N-terminal 
His6 tag may not be optimal for crystal formation. 
 
Chapter 3 – Preparation and NMR Characterization of 15N-labeled SrtApneu  
3.1 Preparation of unlabeled TEV-SrtApneu and 1D 1H-NMR Analysis  
In parallel with our efforts to generate X-ray quality crystals of SrtApneu, we also began 
studies aimed on elucidating the enzyme’s 3D structure using solution NMR. To this end, we first 
generated a new stock of SrtApneu in order to monitor its stability using one dimensional 
1H-NMR. 
Anticipating that we may need to remove the N-terminal His6 tag, a new clone of SrtApneu (TEV-
26 
SrtApneu) was obtained, which included a TEV cleavage site between the His6 tag and the catalytic 
domain. Although numerous publications have demonstrated that His6 tags typically to do not 
perturb protein folding and function, we had contemplated that our inability to effectively 
crystallize SrtApneu may be a repercussion of the flexible His6 tag and thus the TEV cleavage site 
was included as an option.   
Interestingly, and in contrast to the SrtApneu clone used for crystallization trials, we found 
that TEV-SrtApneu yielded sufficient quantities of active monomer without the need for refolding. 
As shown in Figure 14, a band with an appropriate molecular weight was observed following 
simple, non-denaturing IMAC purification, and native-PAGE analysis of the same purification 
revealed significant quantities of both a monomer and dimer. An SDS-PAGE analysis of the 
elution fraction revealed a high intensity band at ~26 kDa of SrtApneu as well as residual higher 
molecular weight polypeptides structures (Figure 14, lane 5). Additionally, we noticed a signature 
pair of bands representing monomeric (bottom) and dimeric (top) enzyme in a native-PAGE gel.  
Figure 14. (Left) SDS-PAGE analysis of non-denaturing IMAC purification of TEV-SrtApneu: (1) 
Protein molecular weight ladder, (2) cell lysate supernatant, (3) flow-through fraction of IMAC column 
under non-denaturing conditions, (4) wash, (5) 1st non-denaturing elution fraction, (6) 2nd non-
denaturing elution fraction. (Right) Native-PAGE analysis of non-denaturing IMAC purification of 
TEV-SrtApneu: (A) cell lysate supernatant, (B) flow-through fraction of IMAC column under non-
denaturing conditions, (C) wash, (D) 1st non-denaturing elution fraction, (E) 2nd non-denaturing elution 
fraction. 
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As noted above, a denaturing IMAC/refolding purification procedure was not applied to 
this protein expression, which provides a rationale for the relatively large band of dimer relative 
to monomer. In order to isolate the desired monomer of TEV-SrtApneu, we relied on a newly 
Figure 15. SEC traces of IMAC purified TEV-SrtApneu (A) and collected monomeric fractions (B). A 
deconvolved mass spectrum (C) of TEV-SrtApneu generated from the corresponding raw ESI-MS 




acquired HiPrep 16/60 Sephacryl 200-HR size exclusion column, which provided excellent 
separation of the TEV-SrtApneu monomer from higher order assemblies (Figure 15A,B). Mass 
spectrometry also confirmed that the isolated protein had the expected molecular weight (Figure 
15C,D). 
To confirm that monomeric TEV-SrtApneu was active, our preparation was subjected to a 
model sortase-mediated ligation (SML) reaction using an Abz-LPATGG-K(Dnp) peptide substrate 
and a strong H2NOH nucleophile to assess in vitro catalytic activity. Previous work from our lab 
revealed that monomeric SrtApneu was catalytically active while dimer was inactive, so we 
anticipated our enzyme stock to behave accordingly. The reactions were analyzed by reverse phase 
liquid chromatography (RP-HPLC) every 30 minutes during a 150-minute incubation period at 
room temperature. The UV/Vis chromatogram for the TEV-SrtApneu monomer revealed a ~65% 
conversion of substrate to modified product, which we deemed as sufficiently active compared to 
the minimal (<5%) product formation of inactive dimer even after a 24-hour incubation (Figure 
Figure 16. RP-HPLC analysis of model SML reaction using TEV-SrtApneu at 0 hr (Black) and after 150 
minutes (Blue). (A) Abz-LPATGG-K(Dnp) substrate. (B) Abz-LPATG-NHOH product. (C) GG-
K(Dnp) excised fragment.  
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16). Overall, these analyses provided evidence that the monomeric form of TEV-SrtApneu was 
indeed an active form of the enzyme, and the form of the enzyme that would be of interest for 
further structural characterization. 
A stock of SrtApneu was concentrated to 450 µM, then used to prepare a 
1H-NMR sample 
including deuterated water (D2O, 10% v/v), ethylenediaminetetraacetic acid (EDTA) and sodium  
azide (NaN3). This sample was subjected to several rounds of 
1H-NMR analysis (512 scans) over 
the course of eight days (4 °C) to monitor conformational stability and report signs of degradation 
(Figure 17). The spectral consistency observed among all acquisitions, in particular within the 
amide N-H region (6-10 ppm) and the aliphatic side chain region (1-3 ppm) suggested that the 
TEV-SrtApneu monomer was stable over lengthy periods of time, and presumably not degrading or 
aggregating into higher order structures.  
 
Figure 17. 1D 1H-NMR analysis of monomeric SrtApneu-TEV over the course of several days.  
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3.2 Expression and Purification of 15N-labeled TEV-SrtApneu 
 
Having established that TEV-SrtApneu remained sufficiently stable in solution, we then 
began generating a stock of isotopically labelled (15N) enzyme for two-dimensional NMR 
characterization. A glycerol stock of transformed E. coli BL21 (DE3) was used to express 15N 
TEV-SrtApneu using a minimal media expression protocol in order to incorporate the 
15N label. 
Briefly, this procedure involves using an overnight seed culture grown in standard LB to initiate a 
large-scale growth, which should be gently centrifuged after an OD600 of 0.5 is reached. The 
pelleted cells are then resuspended in a wash solution to remove residual nutrient rich media, which 
must be performed in a timely manner to avoid significant cellular arrest. The cells are then 
resuspended in minimal media containing 1.5 g of 15N labeled ammonium chloride (15NH4Cl). In 
our hands, initial attempts at expressing 15N-TEV-SrtApneu revealed poor protein yield, which we 
speculate was a consequence of inducing expression too late at an OD600 of ~0.8 or above. By 
inducing expression in the OD600 range of 0.4-0.6 and incubating for 5 hrs at 37 °C, we were able 
to significantly improve protein yields (Figure 18). 
Figure 18. An SDS-PAGE analysis of 15N TEV-SrtApneu: (L) Protein molecular weight ladder. *Band 
corresponding to 15N TEV-SrtApneu. 
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For optimal production of monomeric 15N-TEV-SrtApneu, we once again found that a 
denaturing/refolding protocol was preferred. Thus, as described in section 2.1, cells were first lysed 
under denaturing conditions (8 M urea). This was followed by denaturing IMAC purification, 
refolding, and non-denaturing IMAC purification. As shown in below, an SDS-PAGE analysis of 
the refolded 15N TEV-SrtApneu following non-denaturing IMAC purification revealed an intense 
band between the 20 and 26 kDa molecular weight markers, consistent with the formation of the 
desired 15N-labeled enzyme (Figure 19). This SDS gel displayed a significant monomer 
concentration relative to the residual dimer above. The signature presence of bands representing 
monomer (bottom) and dimer (top) were also observed on a native-PAGE gel, where the monomer 
band intensity was significantly more prominent than all other polypeptides present.  
As a final means of purification, the refolded 15N TEV-SrtApneu was subjected to SEC to 
isolate the monomer. The chromatograms from these SEC separations displayed a monomer peak 
Figure 19. An SDS-PAGE analysis of 15N SrtApneu-TEV refolding IMAC purification scheme (Left): 
(1) Protein ladder. (2) Denatured supernatant. (3) Denatured supernatant flow-through. (4) Denaturing 
wash flow-through. (5) 1st denaturing elution fraction. (6) 2nd denaturing elution fraction. (7) Rapid 
dilution flow-through. (8) Native wash flow-through. (9) 1st native elution fraction. (10) 2nd native 
elution fraction. A native-PAGE analysis of 15N SrtApneu-TEV refolding IMAC purification scheme 
(Right): (A) Denatured supernatant. (B) Denatured supernatant flow-through. (C) Denaturing wash 
flow-through. (D) 1st denaturing elution fraction. (E) 2nd denaturing elution fraction. (F) Rapid dilution 
flow-through. (G) Native wash flow-through. (H) 1st native elution fraction. (I) 2nd native elution 
fraction. 
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significantly larger than dimer (left) and higher molecular weight oligomer (leftmost) peaks. 
Fractions encompassing the right-half of the monomer peak were collected to avoid dimer 
contamination, then concentrated. These fractions were characterized by ESI-MS to confirm the 
identity of the protein, as well as to assess the level of 15N incorporation (Figure 20).  
Figure 20. SEC-FPLC traces of IMAC purified 15N SrtApneu-TEV (A) and collected monomeric 
fractions (B). A deconvolved mass spectrum (C) of 15N SrtApneu-TEV generated from the corresponding 
raw ESI-MS spectrum (D).  
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This result indicated an ~84% isotope incorporation for the lighter mass peak, but the 
heavier mass peak is implying an impossible percent incorporation. Mass readouts by our ESI-MS 
instrument have historically been prone to error when processing biological samples larger than 
peptides, so the observed discrepancy in mass was disregarded and the 20,950.5 Da mass was 
assumed to resemble ~100% isotope incorporation of SrtApneu-TEV. Although the ESI-MS 
readouts didn’t reliably report the extent of SrtApneu-TEV isotopic labelling, we anticipated this 
enzyme stock to be sufficient for HSQC NMR. 
To ensure that the monomeric 15N TEV-SrtApneu preparation was active, it was subjected 
to a model sortase-mediated ligation reaction using an Abz-LPATG-GK(Dnp) peptide substrate 
and a strong H2NOH nucleophile. The reaction was analyzed via RP-HPLC after an overnight 
incubation at room temperature and compared to a control immediately acquired after additional 
of the enzyme (i.e. time = 0 h). The UV/Vis chromatogram reported an ~82% conversion of 
substrate to modified product, which is in excellent agreement with previous model reactions using 
Figure 21. RP-HPLC analysis of model SML reaction using 15N SrtApneu-TEV at 0-hr (Black), at 1-hr 
(Cyan), and after 24-hrs (Marine). (A) Abz-LPATGG-K(Dnp) substrate. (B) Abz-LPATG-NH2OH 
product. (C) GG-K(Dnp) excised fragment.  
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unlabeled SrtApneu (Figure 21). Based on these results, we were able to determine that 
incorporating 15N isotopes into TEV-SrtApneu did not adversely affect its catalytic activity, which 
also suggested that its structure was relatively unperturbed.  
 
3.3 2D-HSQC NMR analysis of 15N-labeled TEV-SrtApneu  
With a purified sample of monomeric 15N TEV-SrtApneu in hand, we turned our attention 
to the acquisition 15N-HSQC spectra. For our initial sample, 15N TEV-SrtApneu was concentrated 
to 98 µM, and then combined with D2O (10% v/v), EDTA (0.5 mM) and NaN3 (0.02% w/v) prior 
to NMR analysis. The acquired spectrum displayed a number of resonances within the expected 
chemical shift range along the 15N axis (100-130 ppm), however the resolution of many signals, 
particularly within a central cluster of peaks was poor (Figure 22). While the lack of resolution 
made it difficult to discern every signal, we detected ~125 unique resonances, which unfortunately 
was well below the more than 200 unique cross peaks we had anticipated for the full-length protein. 
Based on this result, we hypothesized that the resolution of 1H-15N couplings could be improved 
by modulating the acquisition temperature. Therefore, 15N-HSQC spectra were acquired at 15 and 
45 °C. Unfortunately, neither temperature improved the quality of the spectra.  Lowering the 
temperature reduced the resolution of peaks centered within the cluster, and raising the temperature 







Figure 22. 2D HSQC NMR acquisitions of 15N SrtApneu-TEV (98 µM) at RT (Red) and 15 °C (Blue). 
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Next, we attempted to improve the resolution of the 15N-HSQC spectrum by adjusting the 
enzyme concentration. This idea was based on the possibility that the enzyme may exist in solution 
as an equilibrium between monomeric and higher order aggregates, and therefore adjusting the 
concentration may alter the ratio between those species. First, we prepared a 5x diluted sample 
derived from our original 98 µM enzyme stock. In this case, the NMR was unable to detect any 
1H-15N signatures, likely due to the lower overall concentration and corresponding reduction in 
signal-to-noise. We then proceeded to generate a more concentrated (225 µM) stock of 15N TEV-
SrtApneu and were encouraged to see a 
15N-HSQC spectrum with smooth and well-defined contours 
outlining the perimeter of peaks (Figure 23). However, peaks in the center of the cluster remained 
largely undefined, and therefore unsuitable for resonance assignment and structure determination.  
Figure 23. 2D HSQC NMR acquisition of 15N SrtApneu-TEV (225 µM) at RT. 
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Given that increasing the enzyme concentration did not entirely alleviate the resolution 
issues with our spectrum, we speculated that the poorly defined central cluster of peaks may be 
the result of conformationally labile portions of the enzyme, for example at the N-terminus where 
a TEV cleavage site and His6 tag were present. To begin to probe this, we first generated a 
15N-
labeled version of SrtApneu lacking the TEV cleavage site, but retaining the His6 tag. This protein 
was prepared and characterized following the same protocol for 15N TEV-SrtApneu. A concentrated 
stock (171 µM) of SrtApneu without a TEV cleavage site was generated, and an NMR sample was 
prepared with standard conditions. 
The acquired 15N-HSQC spectrum did yield some improvement and unique ~175 peaks 
were observed, including the appearance of new peaks around the exterior of the peak cluster a 
more resolved interior peak cluster as compared to 15N TEV-SrtApneu (Figure 24). While this slight 
improvement in resolution was encouraging, this sample SrtApneu lacking a TEV cleavage site still 
Figure 24. 2D HSQC NMR acquisition of 15N SrtApneu (171 µM) at RT. 
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did not provide sufficient resolution for determining the structure of SrtApneu as there remained a 
significant margin of error for discerning individual peaks within the central cluster. 
 
As a final means of probing the impact of the enzyme N-terminus, we also used TEV 
protease to generate a sample of 15N SrtApneu (80.5 µM) lacking both the TEV cleavage site and 
the His6 tag. While TEV cleavage was successful, as indicated by ESI-MS, the resulting the 
15N-
HSQC spectrum did not provide significant improvements in signal resolution (Figure 25).  
Overall, while we have successfully generated a sample of 15N-labeled enzyme that is 
active and appears to be monomeric, we have yet to acquire two-dimensional data that is suitable 
for full resonance assignment and subsequent structure determination. The reasons for this are not 
entirely clear, however we speculate that portions of SrtApneu may be conformationally labile in 
solution, leading to poorly defined regions in the 15N-HSQC spectrum. Consistent with this 
Figure 25. 2D HSQC NMR acquisition of TEV-cleaved 15N SrtApneu (80.5 µM) at RT. 
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interpretation, we note that the central cluster of poorly defined peaks falls within the range of 
110-125 ppm on the 15N axis, which is where disordered regions of proteins are often observed.  
We also note that regions of disorder have been observed in sortase A homologs in other 
organisms, for example in the case of sortase A from S. aureus where binding of the LPXTG 




Chapter 4 – Progress Toward Preparation of Substrate-docked derivatives of 
SrtApneu 
4.1 – Design and Synthesis of ketomethylene isosteres 
In addition to determining the structure of SrtApneu in the absence of substrate, we have 
also been pursuing strategies for generating enzyme bound to substrate mimetics in order to clearly 
delineate the interactions between the sorting motif and the enzyme active site. As described in 
Chapter 1, structures of sortase A from S. aureus and B. anthracis have been reported in which the 
enzymes are bound to a substrate analog that mimics the acyl enzyme intermediate. This approach 
has provided excellent insight into the recognition of the first four residues of the LPXTG sorting 
motif, however it fails to clearly identify contacts that dictate substrate selectivity involving the 5th 
position (often G) of the sorting signal. To address this issue, previous work in the Antos lab sought 
to replace the scissile amide linkage between the 4th and 5th position residues with a non-cleavable 
carbon-carbon bond. Specifically, a ketomethylene dipeptide isostere (5-aminolevulinic) was 
incorporated into a peptide substrate in place of the native threonine and glycine residues (Figure 
26).  
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 Preliminary evaluation showed that this substrate was not cleaved by SrtApneu, and 
additionally it was able to inhibit enzyme activity was added to a model in vitro reaction.70 While 
encouraging, it was recognized that 5-aminolevulinic was not the optimal diketomethylene 
building block for this approach as it mimicked a diglycine dipeptide structure without any of the 
relevant amino acid side chains.   
Figure 26. Structural comparison of a model LPATG substrate to a 1st generation inhibitor substrate. 
The 4th and 5th position residues of the model substrate have been replaced with a ketomethylene linked 
diglycine.  
Figure 27. Structural comparison of 1st generation and 2nd generation inhibitor substrates. The 4th 
position residue of the 1st generation substrate has been replaced with an alanine to serve as an improved 
mimic of the preferential 4th position threonine.  
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To address this limitation, we sought to develop a synthetic approach for preparing 
diketomethylene analogs that included substituents in positions that mirrored natural amino acids.  
Moreover, we wanted to prepare building that would be compatible with standard solid-phase 
synthesis techniques. To that end, we designed ketomethylene analog A[keto]G as an initial 
synthetic target, which would mimic an alanine-glycine dipeptide rather than a glycine-glycine 
dipeptide (Figure 27). 
We adopted a synthetic strategy by Budnjo et al.1 and Mathieu et al.2 in order to produce 
analog 4 (Figure 28). The synthesis began by combining excess lithium enolate of t-butyl acetate 
and carbonyldiimidazole (CDI)-activated Boc-Ala-OH in the presence of a 4-dimethylamino- 
pyridine (DMAP) catalyst. The resulting Boc-ketoester (1) was isolated in 70% yield, and then 
used as a nucleophile in a stereospecific substitution of a triflate (2) derived from t-butyl-2-
hydroxyacetate. Triflate (2) was prepared separately using t-butyl-2-hydroxyacetate, triflic 
anhydride and 2,6-lutidine. Deprotonation of the Boc-ketoester by excess NaH, followed by drop-
wise addition of 2 resulted in the production of Boc-ketomethylene (3) (41% yield). The identity 
of Boc-ketomethylene (3) was confirmed by proton nuclear magnetic resonance spectroscopy (1H-
Figure 28. Overview of the proposed synthetic scheme based on procedures from Budnjo et al. and 
Mathieu et al. using a Boc-protected amino acid starting material.  
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NMR), as well as low resolution LC-ESI-MS which reported a molecular weight consistent with 
the Na2+-adduct of the Boc-ketomethylene. Subsequent exposure to trifluoroacetic acid (TFA) 
provided a means to remove t-butyl ester and Boc protecting groups, which was followed by an 
in-situ decarboxylation to generate an unprotected precursor. This intermediate was not isolated 
and was immediately reprotected using Fmoc-OSu in the presence of excess 
diisopropylethylamine (DIPEA). While the formation of the target compound (4) was confirmed 
via low resolution LC-ESI-MS and 1H-NMR, overall yields were very poor (<7%) and indicated 
the need for further synthesis optimization. 
Optimization of the reaction cascade began by focusing on the synthesis of Boc-
ketomethylene (Table 4).  Alternate bases (KOtBu or LiHMDS) were used in place of NaH, and 
the replacement of THF with DMF was also attempted. Unfortunately, all variations produced 
lower yields than the original reaction conditions. We then tried to replace the sensitive t-butyl-2-
hydroxyacetate triflate (2) with the less reactive and commercially available t-butyl bromoacetate, 
and were encouraged to observe significant improvements in Boc-ketomethylene yield. 
 
Table 4. Summary of Boc-Ketomethylene reaction optimization results. 
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Next, we sought to investigate the Fmoc reprotection step used to generate the final 
ketomethylene product (Figure 29). Using the Fmoc protection of 5-aminolevulinic acid as a 
model, we found that replacement of DIPEA with sodium carbonate (Na2CO3) and the use of 0.96 
eq of Fmoc-OSu improved gave acceptable reaction yields. 
Unfortunately, use of these conditions to prepare the final ketomethylene target (A[keto]G) 
did not significantly increase the amounts we were able to recover, as purification via column 
chromatography consistently failed to produce entirely pure product, despite variations in eluent, 
the inclusion of 0.1% acetic acid in the mobile phase, or the use of dry loading techniques. 
While the synthesis of 4 remained problematic, we felt that some initial proof-of-concept 
work on its incorporation into a substrate analog were warranted to establish whether any 
additional synthesis optimization would be worthwhile. Thus, a large-scale SPPS preparation of 4 
Figure 29. Reaction scheme for synthesizing a G[keto]G building block for SPPS.  
Figure 30. Synthesis of 2nd generation ketomethylene substrate analog using the A(keto)G building 
block (highlighted) to install a non-cleavable linkage between 4th and 5th residues. 
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beginning with 300 mg of 3 was performed, resulting in the recovery of 200 mg of the final Fmoc-
protected product (<73% yield), which was confirmed by both 1H-NMR and low-resolution LC-
ESI-MS. This provided enough material for use in solid-phase synthesis, which was initiated using 
Rink amide resin and a standard Fmoc-based approach (Figure 30). Unfortunately, following 
cleavage of the crude peptide from the resin, no evidence for the formation of the desired substrate 
analog would be detected by LC-ESI-MS or RP-HPLC. Overall, this prompted us to abandon this 
approach and redirect efforts to the alternate substrate analog design described below. 
 
4.2 – Third generation design using disulfide linked analog  
Having struggled with synthesis of a ketomethylene-containing substrate analog, we 
developed an alternate strategy for generating a substrate bound analog of SrtApneu that relied 
entirely on standard amino acid residues and standard solid-phase synthetic techniques. This 
strategy involves replacing the standard LPATG motif with a derivative containing cysteine (C) in 
place of the native threonine (T) (Figure 31).  
Figure 31. Structural comparison of a model LPATG substrate to a 3rd generation inhibitor substrate. 




Subsequently, disulfide bond formation with the enzyme active site would be used to 
anchor the peptide. While this approach would yield a somewhat artificial enzyme analog that does 
not exactly reproduce all the contacts between enzyme and substrate, this approach has been 
reported in the context sortase A from S. aureus and shown to provide a means for identifying 
enzyme residues by solution NMR that are likely to be involved in substrate recognition. 
Additionally, we hypothesized that the presence of a substrate analog could serve to stabilize the 
enzyme structure, and alleviate the disorder observed in 15N-HSQC spectra of the free enzyme 
described in Chapter 3.  
 
Work on this approach began by synthesizing a Bz-GLPACGG peptide using standard solid phase 
synthesis. The peptide was purified by RP-HPLC, and its identity was confirmed by LC-ESI-MS 
(Figure 32).. With the peptide in hand, we then activated the cysteine by conversion to a mixed 
disulfide using 2,2’-dithiopyridine. Quantitative formation of the mixed disulfide was clearly 
evident after 30 minutes as determined by LC-ESI-MS, and the product was subsequently isolated 
by RP-HPLC. Test reactions were then performed in which the thiopyridyl modified peptide was 
combined TEV-SrtApneu in various ratios (2-50 equivalents) at room temperature. Using LC-ESI-
MS, it was observed that an excess of peptide (50 equiv.) was ideal for rapid and quantitative 



















Figure 32. Shown above is a reaction for generating a Bz-GLPACGG peptide appended to a 
thiopyridine group. RP-HPLC/LC-ESI-MS analysis for determining the purity and molecular weight of 









Figure 33. Shown above is a reaction for appending Bz-GLPACGG to the active-site cysteine of 
SrtApneu. Deconvolved mass spectra of unmodified SrtApneu (A) and substrate bound enzyme (B). 
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Chapter 5 – Conclusion and Future Directions 
The results reported in this thesis describe our progress toward characterizing the structure 
of SrtApneu bound to a substrate. Chapter 2 detailed the utilization of x-ray crystallography to 
determine the unbound structure of SrtApneu, which began by employing methods of reducing the 
assembled forms of the enzyme by denaturing IMAC purification and isolating the monomer by 
SE-FPLC. Spin concentrated monomeric preparations were subjected to INDEX and PEG/Ion2 
screening kits, which revealed several crystal hits featuring Bis-Tris as a component of each 
condition. Therefore, we anticipated that the presence of Bis-Tris favored crystal formation and 
endeavored toward optimizing the screening conditions in an effort to grow diffractable crystals.  
 
Among all of the optimization trials we had attempted, crystal growth appeared to be 
significantly dependent on pH and PEG 3350 concentration. In particular, our top candidates were 
grown in conditions with a pH ranging from 4.5-5.5, and concentrations of PEG 3350 between 24-
26%. Other optimization trials we had conducted devaited Bis-Tris, or tuning salt, concentrations 
as well as alternative enzyme to mother liquor hanging drop compositions. We had even tried 
exploring chloride-containing conditions not included within the preliminary screening kits, but 
we were still unable to find an optimal crystal condition. Regardless, we sought to diffract the 
suboptimal crystals generated thus far, however, we were unable to glean any structural 
information.  
 
In consideration of the theory guiding crystal packing, even the slightest presence of 
dimeric SrtApneu may have significantly perturbed unit cell assembly of monomers. This may 
provide a rationale for our challenges with protein crystallization, where the enzyme stock may be 
more at fault than the conditions we had employed. To our credit, we prepared the sample to the 
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best of our ability considering our experiences with dimeric SrtA persisting regardless of 
denaturing and reducing preparations as well as the poor resolution afforded by our size exclusion 
column. Taken together, we were unable to solve the structure of unbound SrtApneu via x-ray 
crystallography in a timely manner, which propelled our efforts toward utilizing solution NMR as 
described in Chapter 3.  
 
Chapter 3 detailed our efforts toward characterizing the structure of substrate-bound 
SrtApneu by solution NMR, which began by utilizing standard IMAC purification and SEC isolation 
of monomeric SrtApneu-TEV. We opted to express a SrtApneu construct with a TEV cleavage site 
prior to the N-terminal His6 tag in the anticipation that its presence may perturb native folding. 
Initially, we sought to determine if SrtApneu-TEV is conformationally stable over the course of 
several days, as we were concerned for the integrity of enzyme stocks moving forward to numerous 
lengthy HSQC acquisitions. We were confident that SrtApneu-TEV remained stable based on the 
spectra consistency observed in the amide region reported by several 1D 1H-NMR acquisitions.  
 
Next, we redirected our efforts toward expressing our construct in minimal media to 
isotopically label SrtApneu-TEV with 
15N for prospective HSQC NMR. The overall success of the 
isotopically labelled protein expression was largely dependent on the OD600 (0.4-0.6) of the 
minimal media prior to inducing expression with IPTG, and the period of expression (5 hrs). These 
efforts generated a 98 µM stock of 15N SrtApneu-TEV, where HSQC acquisition revealed a cluster 
of poorly resolved peaks containing approximately 125 peaks. LC-ESI-MS of 15N SrtApneu-TEV 
demonstrated a high degree of isotope incorporation, which was inconsistent with the number of 
couplings reported by our HSQC spectrum. Based on the advice of our NMR collaborator, we 
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subjected the 98 µM enzyme stock to 15 °C and 45 °C during acquisition to observe improvements 
in the resolution. Unfortunately, lowering the temperature did not enhance the spectral resolution, 
and increasing the temperature caused the enzyme to precipitate out of solution.  
 
Sequential HSQC acquisitions of a stock with a significantly higher concentration resulted 
in refinement of peaks confined in the perimeter of the cluster, however, the cluster interior 
remained largely undefined and the number of observable couplings was unchanged. We suspected 
that insertion of the TEV recognition sequence may have compromised the folding dynamics of 
the enzyme. Accordingly, we expressed isotopically labeled a SrtApneu construct lacking a TEV-
site. HSQC acquisition of SrtApneu displayed the appearance of 50 new peaks in addition to those 
observed previously. Although promising, the removal of the TEV-site did not facilitate detection 
of all 1H-15N couplings implied by preliminary MS data. Furthermore, HSQC acquisition of a TEV 
cleaved 15N SrtApneu-TEV expression construct provided no indication of improvement. 
 
 Taken together, the evidence suggested that neither His6 tag nor TEV-site was the direct 
cause of our resolution dilemma. Rather, we hypothesized the possibility that active unbound 
SrtApneu could exist as multiple transient conformations compared to the stable substrate-bound 
acyl-enzyme intermediate. We began to justify our complications with enzyme crystallization and 
poor HSQC resolution based on the premise that the in vitro behavior of the active enzyme is more 
dynamic than we had initially anticipated. As discussed in Chapter 4, we sought to design a non-
cleavable peptide analog to dock in the active site in order to stabilize the acyl-enzyme 




Chapter 4 encompassed the synthesis of 2nd and 3rd generation peptide inhibitors for their 
use towards determining the structure of substrate-bound SrtApneu-TEV via solution NMR. 
Previous efforts had demonstrated a reasonable capacity for 1st generation LPA[G(keto)G]G 
inhibitors to compromise the activity of SrtApneu in the presence of a model substrate and 
nucleophile. However, the suboptimal efficacy of this proof of concept inhibitor was reflective of 
missing active site contacts with canonical Thr and Ala residues in the 4th and 5th positions of the 
substrate, respectively. Attempts to synthesize the 2nd generation LPA[A(keto)G]G peptide analog 
were founded on prior efforts toward generating a ketomethylene-linked dipeptide isostere 
mimicking Ala and Gly, which more closely resembled a model LPATAG substrate upon SPPS 
incorporation.  
 
The original synthesis cascade of an SPPS amenable Fmoc protected [A(keto)G] construct 
was burdened by a very poor overall yield. The most notable alteration in the procedure that led to 
improved yields involved the substitution of t-Bu-2-hydroxyacetate triflate for t-Bu-bromoacetate, 
which also abrogated the necessity for triflate preparation prior to Boc-ketoester synthesis. 
Numerous rounds of optimization afforded a sizeable stockpile of Fmoc-[A(keto)G], but we were 
unable to successfully incorporate it into a peptide via SPPS. Prior to SPPS, we had confirmed the 
identity of Fmoc-[A(keto)G] by 1H-NMR and LC-ESI-MS. In theory, Fmoc-[A(keto)G] should be 
behave similarly to our commercially acquired SPPS coupling agents and we’ve yet to develop an 
explanation for our observations.  
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Having struggled with the synthesis of the 2nd generation peptide analog, we developed an 
alternative 3rd generation substrate design based on standard amino acid residues and standard 
solid-phase synthetic techniques. This strategy involved replacing the 4th position threonine of a 
model LPATG substrate with cysteine, where the enzyme active site cysteine was anticipated to 
form a disulfide bridge upon substrate docking. Therefore, characterization of substrate-bound 
SrtApneu-TEV would demonstrate key binding interactions with the 5
th position residue, beyond 
the contacts established by the first four residues reported by Suree et al. (PDB ID: 2KID). A Bz-
GLPACGG-NH2 peptide prepared with a thiopyridine leaving group in the 4
th position cysteine 
was successfully synthesized and demonstrated the capacity to covalently bind to SrtApneu using 
excess substrate leaving miniscule traces of unbound enzyme.  
 
 Considering that the 3rd generation peptide was capable binding to SrtApneu, future efforts 
should be directed toward observing if the peptide is accepted by 15N SrtApneu-TEV. Upon 
confirming the identity of substrate-bound enzyme via LC-ESI-MS, subsequent steps include 
isolating the substrate-enzyme complex, determining the lifetime, followed by HSQC acquisition. 
If the appearance of highly resolved (>200) peaks is observed, then our hypothesis pointing blame 
on enzyme mobility for compromising peak detection and resolution would likely be correct. 
Lastly, a 3D NMR would be acquired to begin assigning peaks to individual amino acids 
composing the enzyme primary sequence. Based on this analysis, we may finally assess active site 
residues prompting key interactions with each position along the substrate.  
 
 Regardless of the shortcomings discussed in this thesis, we’ve been able to establish a 
foundation for unveiling aspects of SrtApneu specificity and structural characterization that are not 
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currently reported in literature. Pursuance of determining the structure of substrate-bound SrtApneu 
with our 3rd generation peptide analog may reveal unpublished active site interactions with the 5th 
position residue. In light of this, we may begin to assemble a complete understanding of SrtA 
substrate specificity based on published interactions with the first four substrate residues and our 
newly reported 5th position contacts. As we continue to develop a structure-function relationship 
for SrtA homologs, we can begin to utilize their unique properties to expand the scope of sortase 
mediated ligation.   
 
Chapter 6 – Experimental 
6.1 Expression of SrtApneu 
The following construct was obtained via commercial gene synthesis from DNA 2.0. 






The following construct was obtained via commercial gene synthesis from ATUM. 






Non-Isotopically Labelled SrtApneu Expression: A 50 uL aliquot of BL21(DE3) cells in 50% 
glycerol containing the plasmid for SrtApneu was added to 50 mL of LB broth containing 100 
µg/mL ampicillin and incubated with shaking at 37 °C overnight. Roughly 25 mL of culture was 
then added per 1 L of LB broth containing 100 µg/mL ampicillin to initiate largescale growth. This 
culture was allowed to grow to an OD600 reading of 0.7-0.8 at 37 °C in a shaking incubator (210 
RPM) before induction with 1 mL of 1 M IPTG. Cells remained at 37 °C with shaking for at least 
three hours to express SrtApneu, and were then isolated by centrifugation at 6000 RPM. Pelleted 
cells were subsequently stored at -80 °C.  
 
Minimal Media Isotopically Labeled SrtApneu Expression: A 50 uL aliquot of BL21(DE3) cells in 
50% glycerol containing the plasmid for SrtApneu-TEV-His6  was added per 50 mL of LB broth 
containing 100 µg/mL kanamycin to initiate a 100 mL seed culture growth, which was incubated 
with shaking (210 RPM) at 37 °C overnight. Roughly 25 mL of culture was added per 1 L of LB 
broth containing 100 µg/mL kanamycin to initiate a large scale 4 L growth. This culture was 
allowed to grow to an OD600 reading of 0.4-0.5 at 37 °C in a shaking incubator (210 RPM), and 
cells were isolated by centrifugation at 4000xg for 20 minutes at 4 °C. Pelleted cells were 
resuspended in 500 mL of a 1 L salt wash (22 mM Na2PO4, 22 mM KH2PO4, 8.6 mM NaCl, 1 mM 
MgCl2, 2.5 μM B1 Vitamin, 100 μM CaCl2, 100 ug/mL kanamycin) solution, and cells were 
isolated by centrifugation at 4000xg for 20 minutes at 4 °C. Pelleted cells were resuspended in 500 
mL of minimal growth media (22 mM Na2PO4, 22 mM KH2PO4, 8.6 mM NaCl, 1 mM MgCl2, 2.5 
μM B1 Vitamin, 100 μM CaCl2, 100 ug/mL kanamycin, 25 mM D-glucose, 27.5 mM 
15N-NH4Cl), 
and the culture was allowed to grow to an OD600 reading of 0.6 at 37 °C in a shaking incubator 
(210 RPM) before induction with 1 mL of 1 M IPTG. Cells remained at 37 °C with shaking for 
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five hours to express 15N SrtApneu, and were then isolated by centrifugation at 5000 RPM for 20 
minutes at 4 °C. Pelleted cells were subsequently stored at -80 °C.  
 
Native purification:  Frozen cell pellets were resuspended in 30 mL denaturing lysis buffer (50 
mM Tris pH 7.5, 150 mM NaCl, 0.5 mM EDTA). The resuspended cells were sonicated for two 
30 second intervals at 50% power output and the lysate was clarified by centrifugation at 17,500 
RPM (Thermo Scientific Fiberlite F20-12x50 LEX rotor). This clarified lysate was added to 5 mL 
of His-Bind resin (Thermo-Fisher) column pre-equilibrated in denaturing wash buffer (50 mM Tris 
pH 7.5, 150 mM NaCl, 20 mM imidazole). Bound protein was washed with 10 column volumes 
of wash buffer and then eluted in two 1 column volume portions of denaturing elution buffer (50 
mM Tris pH 7.5, 150 mM NaCl, 300 mM imidazole). Collected fractions were analyzed by native 
and SDS-PAGE. SrtApneu monomer was further purified on an NGC FPLC system (Bio-Rad) by 
size-exclusion chromatography using an Enrich SEC 70 column (Bio-Rad) with running buffer 
(50 mM Tris pH 7.5, 150 mM NaCl) or a HiPrep 16/60 Sephacryl 200-HR column as the eluent at 
either 0.2 mL/min or 0.5 mL/min. Monomeric protein fractions were pooled, and if necessary, 
concentrated using centrifugal concentrators (10 KDa MW cutoff). Samples were stored at 4 °C 
for temporary storage or -20 °C for long term storage. 
 
Refolding Purification: Frozen cell pellets were resuspended in 30 mL denaturing lysis buffer (50 
mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP, 0.5 mM EDTA, 8 M urea). The resuspended cells 
were sonicated for two 30 second intervals at 50% power output and the lysate was clarified by 
centrifugation at 17,500 RPM. This clarified lysate was added to 5 mL of His-Bind resin (Thermo-
Fisher) column pre-equilibrated in denaturing wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 
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mM TCEP, 20 mM imidazole, 8 M urea). Bound protein was washed with 10 column volumes of 
wash buffer and then eluted in two 1 column volume portions of denaturing elution buffer (50 mM 
Tris pH 7.5, 150 mM NaCl, 1 mM TCEP, 300 mM imidazole, 8 M urea). The first eluted fraction 
was then rapidly diluted (100x) by addition to dilution buffer (50 mM Tris pH 7.5, 150 mM NaCl, 
1 mM TCEP). This material was then recirculated through a 5 mL Ni-NTA column equilibrated 
in native wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP, 20 mM imidazole). Bound 
protein was further washed with 10 column volumes of native wash buffer, then eluted in two 1 
column volume aliquots of native elution buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP, 
300 mM imidazole). Collected fractions were analyzed by native and SDS-PAGE. SrtApneu 
monomer was further purified on an NGC FPLC system (Bio-Rad) by size-exclusion 
chromatography using an Enrich SEC 70 column (Bio-Rad) or a HiPrep 16/60 Sephacryl 200-HR 
column with running buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP) as the eluent at 
either 0.2 mL/min or 0.5 mL/min. Monomeric protein fractions were pooled, and if necessary, 
concentrated using centrifugal concentrators (10 KDa MW cutoff). Samples were stored at 4 °C 
for temporary storage or -20 °C for long term storage. 
 
Evaluation of protein concentration. UV/Vis spectroscopy for determining concentrations of the 
prepared samples was performed on a NanodropTM ND1000 spectrophotometer (Thermo 
Scientific) at 280 nm using 17,420 M-1 cm-1 (SrtApneu) or 18,910 M
-1 cm-1 (SrtApneu-TEV)  as the 




Protein LC-ESI-MS Analysis. Liquid chromatography electrospray ionization mass spectrometry 
(LC-ESI-MS) was performed using a Dionex Ultimate 3000 HPLC system (Thermo Scientific) 
connected to an expressionL high performance compact mass spectrometer (Advion, Inc.) through 
analytical scale separations using a Phenomenex Kinetex 2.6 µm, 100 Å C4 column (2.0 x 100 
mm) with Method B. Data analysis was conducted by Advion Data Express software version 3.0. 
Mass spectrum deconvolution was achieved through a max entropy algorithm to determine 
uncharged masses of samples. 
 
6.2 Protein Crystal Preparations & Diffraction 
Crystallization of SrtApneu. Efforts to produce crystals suitable for x-ray diffraction were grown via 
hanging drop vapor diffusion. All hanging drop loadings were composed of 1:1 mother liquor to 
enzyme (2 μL drop), unless stated otherwise, using a 6 mg/mL SrtApneu stock. PEG/ION2 and 
INDEX screening kits were utilized, and crystal formation was observed under the following 
conditions: 0.2 M sodium acetate pH 7.0 20% w/v PEG 3350 4 °C (C1), 0.2 M sodium formate 
pH 7.0 20% w/v PEG 3350 4 °C (C2), 0.2 M sodium malonate pH 6.0 20% w/v PEG 3350 4°C 
(C3), 0.1 M Bis-Tris pH 5.5 25% w/v PEG 3350 21 °C (C4), 0.1 M Bis-Tris pH 5.5 0.2 M Sodium 
Chloride 25% PEG 3350 21 °C (C5), 0.1 M Bis-Tris pH 5.5 0.2 M Ammonium Acetate 25% w/v 
PEG 3350 21 °C(C6), 0.1 M Bis-Tris pH 5.5 0.2 M Magnesium Chloride hexahydrate 25% w/v 
PEG 3350 21 °C (C7). Room temperature screening conditions (C4-7) were modified by 
optimizing pH, PEG 3350 and salt concentrations, as well as mother liquor:enzyme drop loading 
ratio. Optimization efforts around the C4-7 conditions varied pH (pH 4.5-7.5 in steps of 1 pH, pH 
4.5-5.5 in steps of 0.2 pH) and PEG concentration (18-28% w/v in steps of 2% w/v). Optimization 
of C4 (pH 4.5/5.5) varied Bis-Tris concentrations (0.05-0.30 M in steps of 0.05 M), and 
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optimization of C5-7 (pH 4.5/5.5) varied concentrations of the salts in addition to 0.1 M Bis-Tris 
(0.05-0.2 M in steps of 0.05 M, and 0.2-0.4 M in steps of 0.1 M), where 1:1 (2 uL drop) and 2:1 
(3 uL drop) mother liquor to enzyme ratios were used for C4-7. Furthermore, conditions C4-7 were 
optimized by varying PEG 3350 concentration (20-30% w/v in steps of 2% w/v) and mother liquor 
to enzyme ratio (1:1, 1:2, 2:1, 2:2, 1:3, and 3:1). Observed crystal conditions not evaluated in the 
preliminary screening, yet were anticipated to induce crystal growth, included: 0.1 M Bis-Tris pH 
5.5 0.2 M Potassium Chloride 25% w/v PEG 3350 21 °C (C8), 0.1 M Bis-Tris pH 5.5 0.2 M 
Ammonium Chloride 25% w/v PEG 3350 21 °C (C9), 0.1 M Bis-Tris pH 5.5 0.2 M Calcium 
Chloride 25% w/v PEG 3350 21 °C (C10). Crystal screening of C8-10 (pH 4.5/5.5) involved 
varying concentrations of the salts in addition to 0.1 M Bis-Tris (0.05-0.2 M in steps of 0.05 M, 
and 0.2-0.4 M in steps of 0.1 M).  
 
X-ray Diffraction: Crystals from the following conditions were analyzed via x-ray diffraction: 0.05 
M Bis-Tris pH 5.5 25% w/v PEG 3350 21 °C; 0.25 M Bis-Tris pH 5.5 25% w/v PEG 3350 21 °C, 
0.05 M Bis-Tris pH 5.5 0.05 M Ammonium Acetate 25% w/v PEG 3350 21 °C; 0.1 M Bis-Tris 
pH 5.5 0.15 M Magnesium Chloride hexahydrate 25% w/v PEG 3350 21 °C; 0.1 M Bis-Tris pH 
5.5 0.05 M Sodium Chloride 25% PEG 3350 21 °C. Crystals looped from these conditions were 
cryoprotected by washing each crystal with respective crystal inducing conditions with 30% v/v 
glycerol, followed by immediate flash freezing in liquid nitrogen. All x-ray diffraction data was 





6.3 NMR sample Preparation & Acquisition 
NMR samples contained 50–300 μM of SrtApneu-TEV-His6 or SrtApneu-His6 (unlabeled as well as 
labeled with 15N), which were all prepared under NMR conditions (10% v/v D2O, 0.5 mM EDTA, 
0.02% w/v NaN3). NMR spectra were collected with a Brüker Avance spectrometer at 500 MHz 
for both 1D 1H and 2D HSQC FID processing, and figure generation was done using Mestrelab 
MestReNova software version 10.0.2-15465. 
 
6.4 Synthesis of ketomethylene isosteres 
All chemicals were obtained from commercial sources and were used without further purification. 
NMR spectra were collected with a Brüker Avance spectrometer at 500 MHz for 1H. FID 
processing and figure generation was done using Mestrelab MestReNova software version 10.0.2-
15465. All reactions were performed in flame-dried glassware under argon atmosphere. HPLC 
purification and analysis was performed using a Dionex Ultimate 3000 HPLC system. LC-ESI-
MS was performed with a Dionex Ultimate 3000 HPLC system connected in line to an expressionL 
high performance compact mass spectrometer (Advion, Inc.). Analytical separations for MS 
analysis of synthetic products were achieved with a Phenomenex Kinetex 2.6 µm, 100 Å C18 
column (2.1 x 100 mm) with the following method: MeCN (0.1% formic acid) / 95% H2O, 5% 
MeCN (0.1% formic acid) mobile phase. Flow rate = 0.3 mL/min. Gradient = 5% MeCN (0.0-0.5 
min), 5% MeCN to 90% MeCN (0.5-5.0 min), hold 90% MeCN (5.0-7.0 min), 90% MeCN to 10% 
MeCN (7.0-7.1 min), re-equilibrate to 10% MeCN (7.1-10.0 min).  
 
tert-butyl 2-(((Trifluoromethyl)sulfonyl)oxy)acetate (1). A solution of t-butyl 2-hydroxyacetate 
(0.66 g, 5.0 mmol) in dry DCM (20 mL) was combined with 2,6-lutidine (0.87 mL, 5.0 mmol). 
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The mixture was cooled to 0 °C and triflic anhydride (1.18 mL, 5.0 mmol) was added dropwise 
over 70 minutes, during which time the color changed to light red then orange. After stirring for 1 
hour at 0 °C, the reaction mixture was diluted with n-hexane (100 mL), washed with 1:3 1 M 
HCl/sat. NaCl (3x, 50 mL), and dried over MgSO4. The extract was concentrated by rotary 
evaporation and dried under vacuum to afford the product as a red/orange oil which was used 
without further purification (0.71 g, 41% yield). 1H NMR (500 MHz, CDCl3): δ 4.80 (s, 2H), 1.54 
(s, 9H).  
 
tert-butyl (S)-4-((tert-butoxycarbonyl)amino)-3-oxopentanoate (2). Boc-Ala-OH (1.32 g, 7.0 
mmol) was dissolved in dry THF (20 mL) and then treated with CDI (1.08 g, 7.7 mmol), which 
was added in three portions while stirring, resulting in bubble formation. Within five minutes of 
CDI addition, DMAP (26 mg, 0.21 mmol) was added to the reaction mixture. This was left to stir 
for one hour. In a separate flask, t-butyl acetate (4.1 mL, 28.7 mmol) was added dropwise to 1 M 
LiHMDS (28 mL, 28 mmol) in THF (28 mL) at -78 °C under stirring over the course of ~10 
minutes. This reaction was left to stir for 20 min at -78 °C, and then removed from cooling and 
stirred at room temperature for an additional 10 minutes. The enolate solution was then again 
cooled to -78 °C and stirred for 20 additional minutes, followed by the dropwise addition of the 
CDI-activated Boc-Ala-OH over 10 minutes. The combined reaction was allowed to stir for 1.5 
hrs at -78 °C before being quenched with 10% w/v citric acid (50 mL). The mixture was extracted 
with ethyl acetate (2x, 30 mL), washed with sat. NaHCO3 (30 mL) and sat. NaCl (3x, 30 mL), and 
then dried over MgSO4. After concentration by rotary evaporation, the crude product was purified 
by flash column chromatography (1:3 EtOAc/n-hexane) yielding the product as a white solid (1.38 
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g, 70% yield). 1H NMR (500 MHz, CDCl3): δ 5.15 (m, 1H), 4.38 (m, 1H), 3.46 (q, J = 15.6 Hz, 
2H), 1.46 (s, 9H), 1.44 (s, 9H), 1.36 (d, J = 7.2, 3H). 
 
General procedure for synthesis of di-tert-butyl 2-((tert-butoxycarbonyl)-L-alanyl)succinate (3). 
Boc-Ala ketoester (2) (0.50 g, 1.74 mmol) was dissolved in dry THF (10 mL) and added dropwise 
to a stirred suspension of NaH (60% in mineral oil, 0.126 g, 3.2 mmol) in dry THF (10 mL) at -5 
°C. This mixture was allowed to stir for 20 min, after which t-Bu-bromoacetate (390 µL, 2.64 
mmol) was added at -5 °C. The reaction was allowed to stir overnight at room temperature before 
being quenched with 10% w/v citric acid (15 mL). The quenched reaction was extracted with 
EtOAc (3x, 30 mL) washed with sat. NaCl (90 mL) and dried over MgSO4 before being 
concentrated via rotary evaporation to yield a yellow oil. This residue was purified by flash column 
chromatography with 1:5 EtOAc/hexane and the desired product fractions identified by TLC were 
pooled, and concentrated by rotary evaporation (0.55 g, 79% yield).1H NMR (500 MHz, CDCl3) 
δ 5.24 (dd, J = 13.6, 5.6 Hz, 1H), 4.68-4.44 (m, 1H), 4.11 (ddd, J = 16.9, 8.2, 6.5 Hz, 1H), 2.88-
2.68 (m, 2H), 1.50-1.37 (m, 27H), 1.37-1.33 (m, 3H).  
 
(S)-5-((((9H-fluoren-9-yl)methoxy)carbonyl)-amino)-4-oxohexanoic acid (4). Compound 3 (0.3 
g, 0.747 mmol) was solvated in 10% TFA/DCM (25 mL) and allowed to stir overnight at room 
temperature. After concentrating the resulting mixture by rotary evaporation, the residue was 
dissolved in DCM (10 mL) and reconcentrated by rotary evaporation (3x), after which the 
remaining residue was dried under high vacuum. The vacuum dried residue was then dissolved in 
1:1 water/MeCN (15 mL) and DIPEA (0.375 mL, 2.15 mmol). Fmoc-OSu (0.252 g, 0.747 mmol) 
was then added and allowed to react for 24 hours before the addition of 10 mL of 1 M HCl, which 
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formed a precipitate. The reaction was extracted into DCM (3x, 30 mL), washed with sat. NaCl 
(1x, 30 mL) and dried over MgSO4 before being concentrated under rotary evaporation. The 
residue was solubilized in 3:1 EtOAc/n-hexane and subjected to flash chromatography using 3:1 
EtOAc/n-hexane to purify Fmoc-ketomethylene (4) (0.2 g, 73% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.78 (d, J = 7.5 Hz, 2H), 7.61 (dd, J = 7.6, 3.6 Hz, 2H), 7.45-7.40 (m, 2H), 7.34 (td, J = 
7.5, 1.2 Hz, 2H), 5.53 (d, J = 7.1 Hz, 1H), 4.43 (m, 3H), 4.24 (t, J = 6.8 Hz, 1H), 2.86 (m, 2H), 
2.72 (m, 2H), 1.41 (d, J = 7.2 Hz, 3H). LC-ESI-MS: calculated exact mass 368.14 Da, observed 
368.13 Da. 
 
6.5 Peptide Synthesis & Analysis 
General procedure for solid-phase peptide synthesis. All chemicals were obtained from 
commercial sources and were used without further purification. All peptides were synthesized in 
glass or plastic synthesis vessels. Peptides were synthesized on a 0.1 mmol scale using Rink amide 
MBHA resin. Deprotection was achieved by washing with 20% piperidine/NMP (10 mL, 2x, 20 
min) and was followed by washing with NMP (10 mL, 3x, 10 min). To the deprotected resin, a 
mixture containing an Fmoc protected amino acid (0.3 mmol), HBTU (0.3 mmol) and DIPEA 
solvated in NMP was added, which was left to incubate for 1-24 hrs at room temperature with 
shaking. Unreacted coupling components were removed, and the resin washed with NMP (10 mL, 
3x, 10 min) before repetition of this process to couple all amino acids. Where appropriate, acetyl 
capping of the N-terminus was achieved by combining acetic anhydride (0.3 mmol), DIPEA (0.5 
mmol), and NMP (10 mL), which was added to the resin to couple for 2 hrs. Each peptide generated 
as a substrate for SML reactions contained the 2-aminobenzoyl (Abz) and 2,4-dinitrophenyl (Dnp) 
fluorphore-quencher pair to simplify analysis by UVVis spectroscopy, where Dnp was conjugated 
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to the ε-amine of a lysine side chain [Fmoc-K(Dnp)-OH]. After completion of the peptide, the 
resin was washed with DCM (10 mL, 3x, 10 min) and incubated with cleavage solution (9.5 mL 
TFA, 0.25 mL H2O, 0.25 mL TIPS) for 30 min (5 mL, 2x). The cleaved peptide was collected and 
concentrated via rotary evaporation before being precipitated into dry ice-cooled diethyl ether. The 
precipitate was centrifuged at 4000xg for 5 min and the ether discarded to afford a peptide pellet, 
which was dried under vacuum for 24 hrs. Peptides were solubilized using a mixture of water and 
acetonitrile that was variable based on the amino acid composition. Purification from this state was 
achieved by RP-HPLC with Method A and the molecular weight of the peptides verified via LC-
ESI-MS with Method B. Peptides were lyophilized and resolubilized in 1:1 water/DMSO or 
DMSO to produce stock solutions for use in reactions, which were further analyzed for purity by 
RP-HPLC analysis using Method B. For peptides containing the Dnp chromphore, concentrations 
were estimated by UV/Vis spectroscopy on a NanodropTM ND-1000 spectrophotometer (Thermo 
80 Scientific) at 365 nm using the molar extinction coefficient 17,300 M-1 cm-1 for the Dnp 
chromophore. 
 
Activation of Bz-GLPACGG-NH2 (5). After RP-HPLC purification with Method A and subsequent 
lyophilization, 5 was combined with 2,2’-dipyridyldisulfide (2x) and solvated in NMP. 
Purification of the activated product (6) from reaction mixture was achieved by RP-HPLC with 
Method A, and the molecular weight was verified using LC-ESI-MS with Method B. Purified 6 
was lyophilized and subsequently resolubilized in 1:10 water/DMSO. An aliquot (1 µL) of 6 was 
diluted (100x) in 100 mM DTT and incubated at room temperature for 15-30 minutes. The 
concentration was estimated by UV/Vis spectroscopy on a NanodropTM ND-1000 
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spectrophotometer (Thermo 80 Scientific) at 343 nm using the molar extinction coefficient 8,080 
M-1 cm-1 for the excised 2-mercaptopyridine chromophore. 
 
HPLC purification and analysis was performed using a Dionex Ultimate 3000 HPLC 
system. Semi-preparative separations for the purification of peptides were performed with a 
Phenomenex Luna 5 µm 100 Å C18 column (10 x 250 mm) fitted with a Phenomenex 
SecurityGuard SemiPrep Guard cartridge (10 mm ID). Purification separations were carried out 
with the following method: (Method A): MeCN (0.1% formic acid) / 95% H2O, 5% MeCN (0.1% 
formic acid) mobile phase. Flow rate = 4.0 mL/min. Gradient = 20% MeCN (0.0-2.0 min), 20% 
MeCN to 90% MeCN (2.0-15.0 min), hold 90% MeCN (15.0-17.0 min), 90% MeCN to 10% 
MeCN (17.0-17.01 min), re-equilibrate to 10% MeCN (17.01-19.0 min).  
 
Analytical assessments of peptide purity by UV/Vis, following purification with Method A, were 
performed with a Phenomenex Kinetex 2.6 µm, 100 Å C18 column (2.1 x 100 mm) with the 
method (Method B): MeCN (0.1% formic acid) / 95% H2O, 5% MeCN (0.1% formic acid) mobile 
phase. Flow rate = 0.3 mL/min. Gradient = 10% MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN 
(0.5-5.0 min), hold 90% MeCN (5.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1 min), 
reequilibrate to 10% MeCN (7.1-10.0 min).  
 
LC-ESI-MS was performed with a Dionex Ultimate 3000 HPLC system connected inline to an 
expressionL high performance compact mass spectrometer (Advion, Inc.). Analytical separations 
for UV/Vis and mass spectrometry analysis were performed with a Phenomenex Kinetex 2.6 µm, 
100 Å C18 column (2.1 x 100 mm) with Method B.  
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6.6 Analysis of Enzyme Transpeptidation Activity 
Reactions were prepared by combining all components shown in Table 5. except enzyme, which 
was added to initiate the reaction. Conversion was analyzed by UV/Vis of analytical RP-HPLC 
using a Dionex Ultimate 3000 HPLC system (Thermo Scientific) with a Phenomenex Kinetex 2.6 
µm, 100 Å C18 column (2.1 x 100 mm) with Method B.   
 
Chapter 7 – Literature Cited 
(1)  Rashidian, M.; Dozier, J. K.; Distefano, M. D. Enzymatic Labeling of Proteins: Techniques and 
Approaches. Bioconjug. Chem. 2013, 24 (8), 1277–1294. https://doi.org/10.1021/bc400102w. 
(2)  Koniev, O.; Wagner, A. Developments and Recent Advancements in the Field of Endogenous 
Amino Acid Selective Bond Forming Reactions for Bioconjugation. Chem Soc Rev 2015, 44 (15), 5495–
5551. https://doi.org/10.1039/C5CS00048C. 
(3)  Brannigan, J. A.; Wilkinson, A. J. Protein Engineering 20 Years On. Nat. Rev. Mol. Cell Biol. 2002, 
3 (12), 964–970. https://doi.org/10.1038/nrm975. 
(4)  Lang, K.; Chin, J. W. Bioorthogonal Reactions for Labeling Proteins. ACS Chem. Biol. 2014, 9 (1), 
16–20. https://doi.org/10.1021/cb4009292. 
(5)  Carter, P. Site-Directed Mutagenesis. Biochem. J. 1986, 237 (1), 1–7. 
https://doi.org/10.1042/bj2370001. 
(6)  Könning, D.; Kolmar, H. Beyond Antibody Engineering: Directed Evolution of Alternative Binding 
Scaffolds and Enzymes Using Yeast Surface Display. Microb. Cell Factories 2018, 17 (1), 32. 
https://doi.org/10.1186/s12934-018-0881-3. 
Table 5. Reaction conditions for SML. Water was added to 50 µL total reaction volume unless 
otherwise stated.  
66 
(7)  Caucheteur, D.; Robin, G.; Parez, V.; Martineau, P. Construction of a Synthetic Antibody Gene 
Library for the Selection of Intrabodies and Antibodies. In Phage Display; Hust, M., Lim, T. S., Eds.; 
Springer New York: New York, NY, 2018; Vol. 1701, pp 239–253. https://doi.org/10.1007/978-1-4939-
7447-4_12. 
(8)  Lee, T. C.; Kang, M.; Kim, C. H.; Schultz, P. G.; Chapman, E.; Deniz, A. A. Dual Unnatural Amino 
Acid Incorporation and Click-Chemistry Labeling to Enable Single-Molecule FRET Studies of P97 Folding. 
ChemBioChem 2016, 17 (11), 981–984. https://doi.org/10.1002/cbic.201500695. 
(9)  Lang, K.; Chin, J. W. Cellular Incorporation of Unnatural Amino Acids and Bioorthogonal Labeling 
of Proteins. Chem. Rev. 2014, 114 (9), 4764–4806. https://doi.org/10.1021/cr400355w. 
(10)  Wals, K.; Ovaa, H. Unnatural Amino Acid Incorporation in E. Coli: Current and Future 
Applications in the Design of Therapeutic Proteins. Front. Chem. 2014, 2. 
https://doi.org/10.3389/fchem.2014.00015. 
(11)  Metildi, C. A.; Kaushal, S.; Luiken, G. A.; Talamini, M. A.; Hoffman, R. M.; Bouvet, M. 
Fluorescently Labeled Chimeric Anti-CEA Antibody Improves Detection and Resection of Human Colon 
Cancer in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model: In Vivo Colon Cancer 
Labeling With CEA. J. Surg. Oncol. 2014, 109 (5), 451–458. https://doi.org/10.1002/jso.23507. 
(12)  de Bruin, B.; Kuhnast, B.; Hinnen, F.; Yaouancq, L.; Amessou, M.; Johannes, L.; Samson, A.; 
Boisgard, R.; Tavitian, B.; Dollé, F. 1-[3-(2-[ 18 F]Fluoropyridin-3-Yloxy)Propyl]Pyrrole-2,5-Dione: Design, 
Synthesis, and Radiosynthesis of a New [ 18 F]Fluoropyridine-Based Maleimide Reagent for the Labeling 
of Peptides and Proteins. Bioconjug. Chem. 2005, 16 (2), 406–420. https://doi.org/10.1021/bc0497463. 
(13)  Ducry, L.; Stump, B. Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal 
Antibodies. Bioconjug. Chem. 2010, 21 (1), 5–13. https://doi.org/10.1021/bc9002019. 
(14)  JevsÌŒevar, S.; Kunstelj, M.; Porekar, V. G. PEGylation of Therapeutic Proteins. Biotechnol. J. 
2010, 5 (1), 113–128. https://doi.org/10.1002/biot.200900218. 
(15)  Dozier, J.; Distefano, M. Site-Specific PEGylation of Therapeutic Proteins. Int. J. Mol. Sci. 2015, 16 
(10), 25831–25864. https://doi.org/10.3390/ijms161025831. 
(16)  Mao, H.; Hart, S. A.; Schink, A.; Pollok, B. A. Sortase-Mediated Protein Ligation: A New Method 
for Protein Engineering. J. Am. Chem. Soc. 2004, 126 (9), 2670–2671. 
https://doi.org/10.1021/ja039915e. 
(17)  Beerli, R. R.; Hell, T.; Merkel, A. S.; Grawunder, U. Sortase Enzyme-Mediated Generation of Site-
Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. PLOS ONE 
2015, 10 (7), e0131177. https://doi.org/10.1371/journal.pone.0131177. 
(18)  Chen, Q.; Sun, Q.; Molino, N. M.; Wang, S.-W.; Boder, E. T.; Chen, W. Sortase A-Mediated Multi-
Functionalization of Protein Nanoparticles. Chem. Commun. 2015, 51 (60), 12107–12110. 
https://doi.org/10.1039/C5CC03769G. 
(19)  Antos, J. M.; Chew, G.-L.; Guimaraes, C. P.; Yoder, N. C.; Grotenbreg, G. M.; Popp, M. W.-L.; 
Ploegh, H. L. Site-Specific N- and C-Terminal Labeling of a Single Polypeptide Using Sortases of Different 
Specificity. J. Am. Chem. Soc. 2009, 131 (31), 10800–10801. https://doi.org/10.1021/ja902681k. 
67 
(20)  Roeser, D.; Preusser-Kunze, A.; Schmidt, B.; Gasow, K.; Wittmann, J. G.; Dierks, T.; von Figura, K.; 
Rudolph, M. G. A General Binding Mechanism for All Human Sulfatases by the Formylglycine-Generating 
Enzyme. Proc. Natl. Acad. Sci. 2006, 103 (1), 81–86. https://doi.org/10.1073/pnas.0507592102. 
(21)  Rush, J. S.; Bertozzi, C. R. New Aldehyde Tag Sequences Identified by Screening Formylglycine 
Generating Enzymes in Vitro and in Vivo. J. Am. Chem. Soc. 2008, 130 (37), 12240–12241. 
https://doi.org/10.1021/ja804530w. 
(22)  Wu, P.; Shui, W.; Carlson, B. L.; Hu, N.; Rabuka, D.; Lee, J.; Bertozzi, C. R. Site-Specific Chemical 
Modification of Recombinant Proteins Produced in Mammalian Cells by Using the Genetically Encoded 
Aldehyde Tag. Proc. Natl. Acad. Sci. 2009, 106 (9), 3000–3005. 
https://doi.org/10.1073/pnas.0807820106. 
(23)  Fernández-Suárez, M.; Baruah, H.; Martínez-Hernández, L.; Xie, K. T.; Baskin, J. M.; Bertozzi, C. 
R.; Ting, A. Y. Redirecting Lipoic Acid Ligase for Cell Surface Protein Labeling with Small-Molecule Probes. 
Nat. Biotechnol. 2007, 25 (12), 1483–1487. https://doi.org/10.1038/nbt1355. 
(24)  Slavoff, S. A.; Liu, D. S.; Cohen, J. D.; Ting, A. Y. Imaging Protein–Protein Interactions inside Living 
Cells via Interaction-Dependent Fluorophore Ligation. J. Am. Chem. Soc. 2011, 133 (49), 19769–19776. 
https://doi.org/10.1021/ja206435e. 
(25)  Beckett, D.; Kovaleva, E.; Schatz, P. J. A Minimal Peptide Substrate in Biotin Holoenzyme 
Synthetase-Catalyzed Biotinylation. Protein Sci. 2008, 8 (4), 921–929. 
https://doi.org/10.1110/ps.8.4.921. 
(26)  Algar, W. R.; Prasuhn, D. E.; Stewart, M. H.; Jennings, T. L.; Blanco-Canosa, J. B.; Dawson, P. E.; 
Medintz, I. L. The Controlled Display of Biomolecules on Nanoparticles: A Challenge Suited to 
Bioorthogonal Chemistry. Bioconjug. Chem. 2011, 22 (5), 825–858. https://doi.org/10.1021/bc200065z. 
(27)  Howarth, M.; Takao, K.; Hayashi, Y.; Ting, A. Y. Targeting Quantum Dots to Surface Proteins in 
Living Cells with Biotin Ligase. Proc. Natl. Acad. Sci. 2005, 102 (21), 7583–7588. 
https://doi.org/10.1073/pnas.0503125102. 
(28)  Ton-That, H.; Liu, G.; Mazmanian, S. K.; Faull, K. F.; Schneewind, O. Purification and 
Characterization of Sortase, the Transpeptidase That Cleaves Surface Proteins of Staphylococcus Aureus 
at the LPXTG Motif. Proc. Natl. Acad. Sci. 1999, 96 (22), 12424–12429. 
https://doi.org/10.1073/pnas.96.22.12424. 
(29)  Novick, R. P. Sortase: The Surface Protein Anchoring Transpeptidase and the LPXTG Motif. 
Trends Microbiol. 2000, 8 (4), 148–151. https://doi.org/10.1016/S0966-842X(00)01741-8. 
(30)  Ilangovan, U.; Ton-That, H.; Iwahara, J.; Schneewind, O.; Clubb, R. T. Structure of Sortase, the 
Transpeptidase That Anchors Proteins to the Cell Wall of Staphylococcus Aureus. Proc. Natl. Acad. Sci. 
2001, 98 (11), 6056–6061. https://doi.org/10.1073/pnas.101064198. 
(31)  Bradshaw, W. J.; Davies, A. H.; Chambers, C. J.; Roberts, A. K.; Shone, C. C.; Acharya, K. R. 
Molecular Features of the Sortase Enzyme Family. FEBS J. 2015, 282 (11), 2097–2114. 
https://doi.org/10.1111/febs.13288. 
68 
(32)  Dramsi, S.; Trieu-Cuot, P.; Bierne, H. Sorting Sortases: A Nomenclature Proposal for the Various 
Sortases of Gram-Positive Bacteria. Res. Microbiol. 2005, 156 (3), 289–297. 
https://doi.org/10.1016/j.resmic.2004.10.011. 
(33)  Ton-That, H.; Schneewind, O. Anchor Structure of Staphylococcal Surface Proteins: IV. 
INHIBITORS OF THE CELL WALL SORTING REACTION. J. Biol. Chem. 1999, 274 (34), 24316–24320. 
https://doi.org/10.1074/jbc.274.34.24316. 
(34)  Mazmanian, S. K. Staphylococcus Aureus Sortase, an Enzyme That Anchors Surface Proteins to 
the Cell Wall. Science 1999, 285 (5428), 760–763. https://doi.org/10.1126/science.285.5428.760. 
(35)  Mazmanian, S. K.; Liu, G.; Jensen, E. R.; Lenoy, E.; Schneewind, O. Staphylococcus Aureus Sortase 
Mutants Defective in the Display of Surface Proteins and in the Pathogenesis of Animal Infections. Proc. 
Natl. Acad. Sci. 2000, 97 (10), 5510–5515. https://doi.org/10.1073/pnas.080520697. 
(36)  Mazmanian, S. K.; Ton-That, H.; Schneewind, O. Sortase-Catalysed Anchoring of Surface Proteins 
to the Cell Wall of Staphylococcus Aureus. Mol. Microbiol. 2001, 40 (5), 1049–1057. 
https://doi.org/10.1046/j.1365-2958.2001.02411.x. 
(37)  Marraffini, L. A.; DeDent, A. C.; Schneewind, O. Sortases and the Art of Anchoring Proteins to the 
Envelopes of Gram-Positive Bacteria. Microbiol. Mol. Biol. Rev. 2006, 70 (1), 192–221. 
https://doi.org/10.1128/MMBR.70.1.192-221.2006. 
(38)  Patti, J. M.; Jonsson, H.; Guss, B.; Switalski, L. M.; Wiberg, K.; Lindberg, M.; Höök, M. Molecular 
Characterization and Expression of a Gene Encoding a Staphylococcus Aureus Collagen Adhesin. J. Biol. 
Chem. 1992, 267 (7), 4766–4772. 
(39)  Lalioui, L.; Pellegrini, E.; Dramsi, S.; Baptista, M.; Bourgeois, N.; Doucet-Populaire, F.; Rusniok, C.; 
Zouine, M.; Glaser, P.; Kunst, F.; et al. The SrtA Sortase of Streptococcus Agalactiae Is Required for Cell 
Wall Anchoring of Proteins Containing the LPXTG Motif, for Adhesion to Epithelial Cells, and for 
Colonization of the Mouse Intestine. Infect. Immun. 2005, 73 (6), 3342–3350. 
https://doi.org/10.1128/IAI.73.6.3342-3350.2005. 
(40)  Signas, C.; Raucci, G.; Jonsson, K.; Lindgren, P. E.; Anantharamaiah, G. M.; Hook, M.; Lindberg, 
M. Nucleotide Sequence of the Gene for a Fibronectin-Binding Protein from Staphylococcus Aureus: Use 
of This Peptide Sequence in the Synthesis of Biologically Active Peptides. Proc. Natl. Acad. Sci. 1989, 86 
(2), 699–703. https://doi.org/10.1073/pnas.86.2.699. 
(41)  Vanier, G.; Sekizaki, T.; Domínguez-Punaro, M. C.; Esgleas, M.; Osaki, M.; Takamatsu, D.; Segura, 
M.; Gottschalk, M. Disruption of SrtA Gene in Streptococcus Suis Results in Decreased Interactions with 
Endothelial Cells and Extracellular Matrix Proteins. Vet. Microbiol. 2008, 127 (3–4), 417–424. 
https://doi.org/10.1016/j.vetmic.2007.08.032. 
(42)  Gómez, M. I.; Lee, A.; Reddy, B.; Muir, A.; Soong, G.; Pitt, A.; Cheung, A.; Prince, A. 
Staphylococcus Aureus Protein A Induces Airway Epithelial Inflammatory Responses by Activating 
TNFR1. Nat. Med. 2004, 10 (8), 842–848. https://doi.org/10.1038/nm1079. 
69 
(43)  Cossart, P.; Jonquieres, R. Sortase, a Universal Target for Therapeutic Agents against Gram-
Positive Bacteria? Proc. Natl. Acad. Sci. 2000, 97 (10), 5013–5015. 
https://doi.org/10.1073/pnas.97.10.5013. 
(44)  Bierne, H.; Mazmanian, S. K.; Trost, M.; Pucciarelli, M. G.; Liu, G.; Dehoux, P.; the European 
Listeria Genome Consortium; Jansch, L.; Portillo, F. G.; Schneewind, O.; et al. Inactivation of the SrtA 
Gene in Listeria Monocytogenes Inhibits Anchoring of Surface Proteins and Affects Virulence. Mol. 
Microbiol. 2002, 43 (4), 869–881. https://doi.org/10.1046/j.1365-2958.2002.02798.x. 
(45)  Garandeau, C. The Sortase SrtA of Listeria Monocytogenes Is Involved in Processing of Internalin 
and in Virulence. Infect. Immun. 2002, 70 (3), 1382–1390. https://doi.org/10.1128/IAI.70.3.1382-
1390.2002. 
(46)  Chen, S.; Paterson, G. K.; Tong, H. H.; Mitchell, T. J.; DeMaria, T. F. Sortase A Contributes to 
Pneumococcal Nasopharyngeal Colonization in the Chinchilla Model. FEMS Microbiol. Lett. 2005, 253 (1), 
151–154. https://doi.org/10.1016/j.femsle.2005.09.052. 
(47)  Paterson, G. K.; Mitchell, T. J. The Role of Streptococcus Pneumoniae Sortase A in Colonisation 
and Pathogenesis. Microbes Infect. 2006, 8 (1), 145–153. https://doi.org/10.1016/j.micinf.2005.06.009. 
(48)  Maresso, A. W.; Schneewind, O. Sortase as a Target of Anti-Infective Therapy. Pharmacol. Rev. 
2008, 60 (1), 128–141. https://doi.org/10.1124/pr.107.07110. 
(49)  Theile, C. S.; Witte, M. D.; Blom, A. E. M.; Kundrat, L.; Ploegh, H. L.; Guimaraes, C. P. Site-Specific 
N-Terminal Labeling of Proteins Using Sortase-Mediated Reactions. Nat. Protoc. 2013, 8 (9), 1800–1807. 
https://doi.org/10.1038/nprot.2013.102. 
(50)  Petrache, A. I.; Machin, D. C.; Williamson, D. J.; Webb, M. E.; Beales, P. A. Sortase-Mediated 
Labelling of Lipid Nanodiscs for Cellular Tracing. Mol. Biosyst. 2016, 12 (6), 1760–1763. 
https://doi.org/10.1039/C6MB00126B. 
(51)  Witte, M. D.; Cragnolini, J. J.; Dougan, S. K.; Yoder, N. C.; Popp, M. W.; Ploegh, H. L. Preparation 
of Unnatural N-to-N and C-to-C Protein Fusions. Proc. Natl. Acad. Sci. 2012, 109 (30), 11993–11998. 
https://doi.org/10.1073/pnas.1205427109. 
(52)  Tanaka, T.; Yamamoto, T.; Tsukiji, S.; Nagamune, T. Site-Specific Protein Modification on Living 
Cells Catalyzed by Sortase. ChemBioChem 2008, 9 (5), 802–807. 
https://doi.org/10.1002/cbic.200700614. 
(53)  Popp, M. W.; Antos, J. M.; Grotenbreg, G. M.; Spooner, E.; Ploegh, H. L. Sortagging: A Versatile 
Method for Protein Labeling. Nat. Chem. Biol. 2007, 3 (11), 707–708. 
https://doi.org/10.1038/nchembio.2007.31. 
(54)  van ’t Hof, W.; Maňásková, S. H.; Veerman, E. C. I.; Bolscher, J. G. M. Sortase-Mediated 
Backbone Cyclization of Proteins and Peptides. Biol. Chem. 2015, 396 (4). https://doi.org/10.1515/hsz-
2014-0260. 
(55)  Haridas, V.; Sadanandan, S.; Dheepthi, N. U. Sortase-Based Bio-Organic Strategies for 
Macromolecular Synthesis. ChemBioChem 2014, 15 (13), 1857–1867. 
https://doi.org/10.1002/cbic.201402013. 
70 
(56)  Ritzefeld, M. Sortagging: A Robust and Efficient Chemoenzymatic Ligation Strategy. Chem. - Eur. 
J. 2014, 20 (28), 8516–8529. https://doi.org/10.1002/chem.201402072. 
(57)  Schmohl, L.; Schwarzer, D. Sortase-Mediated Ligations for the Site-Specific Modification of 
Proteins. Curr. Opin. Chem. Biol. 2014, 22, 122–128. https://doi.org/10.1016/j.cbpa.2014.09.020. 
(58)  Voloshchuk, N.; Liang, D.; Liang, J. Sortase A Mediated Protein Modifications and Peptide 
Conjugations. Curr. Drug Discov. Technol. 2016, 12 (4), 205–213. 
https://doi.org/10.2174/1570163812666150903115601. 
(59)  Proft, T. Sortase-Mediated Protein Ligation: An Emerging Biotechnology Tool for Protein 
Modification and Immobilisation. Biotechnol. Lett. 2010, 32 (1), 1–10. https://doi.org/10.1007/s10529-
009-0116-0. 
(60)  Matsumoto, T.; Takase, R.; Tanaka, T.; Fukuda, H.; Kondo, A. Site-Specific Protein Labeling with 
Amine-Containing Molecules Using Lactobacillus Plantarum Sortase. Biotechnol. J. 2012, 7 (5), 642–648. 
https://doi.org/10.1002/biot.201100213. 
(61)  Guimaraes, C. P.; Witte, M. D.; Theile, C. S.; Bozkurt, G.; Kundrat, L.; Blom, A. E. M.; Ploegh, H. L. 
Site-Specific C-Terminal and Internal Loop Labeling of Proteins Using Sortase-Mediated Reactions. Nat. 
Protoc. 2013, 8 (9), 1787–1799. https://doi.org/10.1038/nprot.2013.101. 
(62)  Chen, I.; Dorr, B. M.; Liu, D. R. A General Strategy for the Evolution of Bond-Forming Enzymes 
Using Yeast Display. Proc. Natl. Acad. Sci. 2011, 108 (28), 11399–11404. 
https://doi.org/10.1073/pnas.1101046108. 
(63)  Piotukh, K.; Geltinger, B.; Heinrich, N.; Gerth, F.; Beyermann, M.; Freund, C.; Schwarzer, D. 
Directed Evolution of Sortase A Mutants with Altered Substrate Selectivity Profiles. J. Am. Chem. Soc. 
2011, 133 (44), 17536–17539. https://doi.org/10.1021/ja205630g. 
(64)  Schmohl, L.; Bierlmeier, J.; Gerth, F.; Freund, C.; Schwarzer, D. Engineering Sortase A by 
Screening a Second-Generation Library Using Phage Display: Directed Evolution of Sortase A. J. Pept. Sci. 
2017, 23 (7–8), 631–635. https://doi.org/10.1002/psc.2980. 
(65)  Hirakawa, H.; Ishikawa, S.; Nagamune, T. Design of Ca 2+ -Independent Staphylococcus Aureus 
Sortase A Mutants. Biotechnol. Bioeng. 2012, 109 (12), 2955–2961. https://doi.org/10.1002/bit.24585. 
(66)  Kruger, R. G.; Otvos, B.; Frankel, B. A.; Bentley, M.; Dostal, P.; McCafferty, D. G. Analysis of the 
Substrate Specificity of the Staphylococcus Aureus Sortase Transpeptidase SrtA †. Biochemistry 2004, 43 
(6), 1541–1551. https://doi.org/10.1021/bi035920j. 
(67)  Perry, A. M.; Ton-That, H.; Mazmanian, S. K.; Schneewind, O. Anchoring of Surface Proteins to 
the Cell Wall of Staphylococcus Aureus: III. LIPID II IS AN IN VIVO PEPTIDOGLYCAN SUBSTRATE FOR 
SORTASE-CATALYZED SURFACE PROTEIN ANCHORING. J. Biol. Chem. 2002, 277 (18), 16241–16248. 
https://doi.org/10.1074/jbc.M109194200. 
(68)  Huang, X.; Aulabaugh, A.; Ding, W.; Kapoor, B.; Alksne, L.; Tabei, K.; Ellestad, G. Kinetic 
Mechanism of Staphylococcus Aureus Sortase SrtA. Biochemistry 2003, 42 (38), 11307–11315. 
https://doi.org/10.1021/bi034391g. 
71 
(69)  Dorr, B. M.; Ham, H. O.; An, C.; Chaikof, E. L.; Liu, D. R. Reprogramming the Specificity of Sortase 
Enzymes. Proc. Natl. Acad. Sci. 2014, 111 (37), 13343–13348. 
https://doi.org/10.1073/pnas.1411179111. 
(70)  Nikghalb, K. D.; Horvath, N. M.; Prelesnik, J. L.; Banks, O. G. B.; Filipov, P. A.; Row, R. D.; Roark, T. 
J.; Antos, J. M. Expanding the Scope of Sortase-Mediated Ligations by Using Sortase Homologues. 
ChemBioChem 2018, 19 (2), 185–195. https://doi.org/10.1002/cbic.201700517. 
(71)  Schmohl, L.; Bierlmeier, J.; von Kügelgen, N.; Kurz, L.; Reis, P.; Barthels, F.; Mach, P.; 
Schutkowski, M.; Freund, C.; Schwarzer, D. Identification of Sortase Substrates by Specificity Profiling. 
Bioorg. Med. Chem. 2017, 25 (18), 5002–5007. https://doi.org/10.1016/j.bmc.2017.06.033. 
(72)  Boekhorst, J.; de Been, M. W. H. J.; Kleerebezem, M.; Siezen, R. J. Genome-Wide Detection and 
Analysis of Cell Wall-Bound Proteins with LPxTG-Like Sorting Motifs. J. Bacteriol. 2005, 187 (14), 4928–
4934. https://doi.org/10.1128/JB.187.14.4928-4934.2005. 
(73)  Kruger, R. G.; Dostal, P.; McCafferty, D. G. Development of a High-Performance Liquid 
Chromatography Assay and Revision of Kinetic Parameters for the Staphylococcus Aureus Sortase 
Transpeptidase SrtA. Anal. Biochem. 2004, 326 (1), 42–48. https://doi.org/10.1016/j.ab.2003.10.023. 
(74)  Schleifer, K. H.; Kandler, O. Peptidoglycan Types of Bacterial Cell Walls and Their Taxonomic 
Implications. Bacteriol. Rev. 1972, 36 (4), 407–477. 
(75)  Jacobitz, A. W.; Kattke, M. D.; Wereszczynski, J.; Clubb, R. T. Sortase Transpeptidases: Structural 
Biology and Catalytic Mechanism. In Advances in Protein Chemistry and Structural Biology; Elsevier, 
2017; Vol. 109, pp 223–264. https://doi.org/10.1016/bs.apcsb.2017.04.008. 
(76)  Jacobitz, A. W.; Wereszczynski, J.; Yi, S. W.; Amer, B. R.; Huang, G. L.; Nguyen, A. V.; Sawaya, M. 
R.; Jung, M. E.; McCammon, J. A.; Clubb, R. T. Structural and Computational Studies of the 
Staphylococcus Aureus Sortase B-Substrate Complex Reveal a Substrate-Stabilized Oxyanion Hole. J. Biol. 
Chem. 2014, 289 (13), 8891–8902. https://doi.org/10.1074/jbc.M113.509273. 
(77)  Frankel, B. A.; Kruger, R. G.; Robinson, D. E.; Kelleher, N. L.; McCafferty, D. G. Staphylococcus 
Aureus Sortase Transpeptidase SrtA: Insight into the Kinetic Mechanism and Evidence for a Reverse 
Protonation Catalytic Mechanism †. Biochemistry 2005, 44 (33), 11188–11200. 
https://doi.org/10.1021/bi050141j. 
(78)  Suree, N.; Liew, C. K.; Villareal, V. A.; Thieu, W.; Fadeev, E. A.; Clemens, J. J.; Jung, M. E.; Clubb, 
R. T. The Structure of the Staphylococcus Aureus Sortase-Substrate Complex Reveals How the 
Universally Conserved LP X TG Sorting Signal Is Recognized. J. Biol. Chem. 2009, 284 (36), 24465–24477. 
https://doi.org/10.1074/jbc.M109.022624. 
(79)  Chan, A. H.; Yi, S. W.; Terwilliger, A. L.; Maresso, A. W.; Jung, M. E.; Clubb, R. T. Structure of the 
Bacillus Anthracis Sortase A Enzyme Bound to Its Sorting Signal: A FLEXIBLE AMINO-TERMINAL 
APPENDAGE MODULATES SUBSTRATE ACCESS. J. Biol. Chem. 2015, 290 (42), 25461–25474. 
https://doi.org/10.1074/jbc.M115.670984. 
(80)  Race, P. R.; Bentley, M. L.; Melvin, J. A.; Crow, A.; Hughes, R. K.; Smith, W. D.; Sessions, R. B.; 
Kehoe, M. A.; McCafferty, D. G.; Banfield, M. J. Crystal Structure of Streptococcus Pyogenes Sortase A: 
72 
IMPLICATIONS FOR SORTASE MECHANISM. J. Biol. Chem. 2009, 284 (11), 6924–6933. 
https://doi.org/10.1074/jbc.M805406200. 
(81)  Khare, B.; Krishnan, V.; Rajashankar, K. R.; I-Hsiu, H.; Xin, M.; Ton-That, H.; Narayana, S. V. 
Structural Differences between the Streptococcus Agalactiae Housekeeping and Pilus-Specific Sortases: 
SrtA and SrtC1. PLoS ONE 2011, 6 (8), e22995. https://doi.org/10.1371/journal.pone.0022995. 
(82)  Chambers, C. J.; Roberts, A. K.; Shone, C. C.; Acharya, K. R. Structure and Function of a 
Clostridium Difficile Sortase Enzyme. Sci. Rep. 2015, 5 (1), 9449. https://doi.org/10.1038/srep09449. 
(83)  Marraffini, L. A.; Ton-That, H.; Zong, Y.; Narayana, S. V. L.; Schneewind, O. Anchoring of Surface 
Proteins to the Cell Wall of Staphylococcus Aureus: A CONSERVED ARGININE RESIDUE IS REQUIRED FOR 
EFFICIENT CATALYSIS OF SORTASE A. J. Biol. Chem. 2004, 279 (36), 37763–37770. 
https://doi.org/10.1074/jbc.M405282200. 
(84)  Kappel, K.; Wereszczynski, J.; Clubb, R. T.; McCammon, J. A. The Binding Mechanism, Multiple 
Binding Modes, and Allosteric Regulation of Staphylococcus Aureus Sortase A Probed by Molecular 
Dynamics Simulations: Staphylococcus Aureus SrtA Probed by MD Simulations. Protein Sci. 2012, 21 (12), 
1858–1871. https://doi.org/10.1002/pro.2168. 
(85)  Moritsugu, K.; Terada, T.; Kidera, A. Disorder-to-Order Transition of an Intrinsically Disordered 
Region of Sortase Revealed by Multiscale Enhanced Sampling. J. Am. Chem. Soc. 2012, 134 (16), 7094–
7101. https://doi.org/10.1021/ja3008402. 
(86)  Pang, X.; Zhou, H.-X. Disorder-to-Order Transition of an Active-Site Loop Mediates the Allosteric 
Activation of Sortase A. Biophys. J. 2015, 109 (8), 1706–1715. https://doi.org/10.1016/j.bpj.2015.08.039. 
(87)  Suree, N.; Liew, C. K.; Villareal, V. A.; Thieu, W.; Fadeev, E. A.; Clemens, J. J.; Jung, M. E.; Clubb, 
R. T. The Structure of the Staphylococcus Aureus Sortase-Substrate Complex Reveals How the 
Universally Conserved LP X TG Sorting Signal Is Recognized. J. Biol. Chem. 2009, 284 (36), 24465–24477. 
https://doi.org/10.1074/jbc.M109.022624. 
(88)  Kelley, L. A.; Mezulis, S.; Yates, C. M.; Wass, M. N.; Sternberg, M. J. E. The Phyre2 Web Portal for 
Protein Modeling, Prediction and Analysis. Nat. Protoc. 2015, 10 (6), 845–858. 
https://doi.org/10.1038/nprot.2015.053. 
(89)  Lu, C.; Zhu, J.; Wang, Y.; Umeda, A.; Cowmeadow, R. B.; Lai, E.; Moreno, G. N.; Person, M. D.; 
Zhang, Z. Staphylococcus Aureus Sortase A Exists as a Dimeric Protein In Vitro †. Biochemistry 2007, 46 
(32), 9346–9354. https://doi.org/10.1021/bi700519w. 
(90)  Zhu, J.; Lu, C.; Standland, M.; Lai, E.; Moreno, G. N.; Umeda, A.; Jia, X.; Zhang, Z. Single Mutation 
on the Surface of Staphylococcus Aureus Sortase A Can Disrupt Its Dimerization †. Biochemistry 2008, 47 
(6), 1667–1674. https://doi.org/10.1021/bi7014597. 
(91)  Zhu, J.; Xiang, L.; Jiang, F.; Zhang, Z. J. Equilibrium of Sortase A Dimerization on Staphylococcus 
Aureus Cell Surface Mediates Its Cell Wall Sorting Activity. Exp. Biol. Med. 2016, 241 (1), 90–100. 
https://doi.org/10.1177/1535370215592122. 
73 
(92)  Dekker, N.; Tommassen, J.; Lustig, A.; Rosenbusch, J. P.; Verheij, H. M. Dimerization Regulates 
the Enzymatic Activity of Escherichia Coli Outer Membrane Phospholipase A. J. Biol. Chem. 1997, 272 (6), 
3179–3184. https://doi.org/10.1074/jbc.272.6.3179. 
 
Chapter 8 – Appendix 
 
74 
 
